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Halothane anesthesia, introduced in the 1950's, is today a widely 
used general anesthetic in both veterinary and human medicine. With the 
use of halothane, however, there is a risk of cardiac arrhythmias devel-
oping during surgical procedures. One of the factors implicated in the 
genesis of arrhythmias is the administration of epinephrine (1). To pre-
vent the genesis of fatal arrhythmias, a lidocaine bolus or infusion may 
be given to the patient (2). 
Lidocaine, a local anesthetic, has been shown to be effective in 
the treatment of epinephrine induced cardiac arrhythmias under halothane 
(2). The possible mechanism of action is a decrease in the alterations of 
action potential durations in various regions of the heart induced by halo-
thane and epinephrine. The ionic effects of lidocaine include a delayed 
closure and r•ear.tivation of :fast sodium channels ( 4), increasing outward po-
tassium current neen during spontaneous depolarization (5), and possible 
alterations with the slow inward calcium current (6). 
Xylazine hydrochloride, a potent sedative, also possesses local 
anesthetic activity (7). There are investigators, however, which report 
xylazine and halothane will result in epinephrine arrhythmias in the dog 
(8). A complicating factor in this study, however was the presence of 




The basic assumption in this study is that as local anesthetics, 
both lidocaine and xylazine would have similar mechanisms of action and 
thus similar effects on the cardiac action potential. This in turn would 
affect the response to epinephrine under halothane anesthesia. 
The nature of these changes should be reflected by changes in the 
electrocardiogram, namely, changes in interval duration, wave amplitude 
and heart rate. This study will also compare the dose of epinephrine 
necessary to induce arrhythmia in lidocaine and xylazine treatment 
groups. 
CHAPTER II 
CARDIAC ACTION POTENTIAL 
The ionic mechanisms underlying the cardiac action potential ultima-
tely leading to contraction are multiple and do not seem to have an exact 
counterpart in nerve. These ionic movements are basically the same in 
the entire heart, but there are variations. These variations are related 
to the two basic types of tissue contained within the heart. One is no-
dal tissue which is characterized by clusters of cells supported by col-
lagen and containing a paucity of myofibrils (9, 10). This is in contrast 
to the more regular pattern of the atrial and ventricular cells, which 
contain abundant myofibrils. The nodal tissue, which is part of the con-
ductive tissue of the heart can be subdivided, as well, into basically 
two types, based on their electrophysiologic properties. Those tissues 
which can be classified as automatic typically do not have a stable rest-
ing membrane potential, but undergo a process of spontaneous depolariza-
tion to reach threshold potential (10). Typifying the automatic tissue is 
that of the sinoatrial node (SA) which normally controls heart rate by 
its intrinsic rate of spontaneous depolarization (9). Also known as the 
pacemaker, its action potential has a characteristic slow upstroke and 
low conduction velocity. Although composed of nodal tissue with action 
potential characteristics similar to that of the sinus node, the AV 
(atrioventricular) node does not normally possess automaticity. Cells 
which are not automatic are those comprising the atrial/ventricular mus-
cle and bundle of His Purkinje fiber system. These cells are 
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characterized by a high resting potential and rapid conduction velocities. 
Throughout this discussion, the technique drawn upon to analyze the ionic 
basis of the cardiac action potential is the widely used method of volt-
age clamping. This technique utilizes a procedure of applying a steady 
voltage across the cellular membrane and measuring the resultant current 
flow through the membrane. The theory behind this technique is that a 
sensing electrode also placed through the membrane, senses the change in 
ionic currents as a result of the applied voltage, and alters the applied 
current so as to maintain the membrane potential current constant. The 
result is an equal and opposite current produced to oppose that of the 
ionic movement. This technique, however, only measures the total ionic 
flow and does not provide information concerning individual ionic cur-
rents responsible for that current. In order to analyze the specific 
ion effects, individual ion concentration can be raised or lowered in 
the extracellular fluid or a specific ion free solution can be used (11). 
The characteristics of the cardiac action potential are long dura-
tion (up to 500 msec) and, in at least the Purkinje fiber system, con-
sist of five phases. Each of these phases is associated with specific 
ionic movements ancl as previously mentioned, though all may not have an 
exact counterpart in nerve, some phases do share common mechanisms. The 
investigations concerning the Purkinje fibers will be reviewed first, 
followed by that of the sinoatrial node (9). 
Purkinje Fiber System 
The Purkinje fiber system is normally responsible for the initia-
tion of ventricular depolarization and is a network consisting of large 




The network arises from the atriovontricular bundle and divides into the 
right and left bundle branches at the base of the interventricular septum. 
In this manner, electrical activation is rapidly propagated through the 
ventricles. 
Ionic Mechanisms 
The cardiac cell membrane, as in the nerve, is selective·ly permeable 
to the ions, + ++ -Na , Ca and Cl . To describe the movements between 
intracellular and extracellular fluids, a conceptual model of these pas-
sing through channels has been proposed (11). The ability of these ions to 
move across the membrane depends upon the driving force or electrochemi-
cal gradient and the ability of the ions to pass through the membrane 
(conductance) (11). The ability of the sarcolemma to undergo sequential 
changes in ion conductances results in five phases of the action 
potential, each with its own characteristics (20). 
Phase 4 - Resting Potential. The resting potential or phase 4 of the 
action potential is similar in mechanism in the cardiac cell to that of 
other excitable cells. Thus, the basis for the rest.ing potential can be 
discovered, in terms of the electrochemical gradient for potassium that ex-
ists across the sarcolemma. In the resting state this gradient is such 
that there is a higher intracellular potassium concentration than that of 
the extracellular fluid space. This electrochemical gradient is maintained 
+ + by a sarcolemmal transport system, the Na /K pump (10). In this system, 
the small amount of sodium that enters the cell is exchanged for potassium 
++ by a Mg - dependent ATPase enzyme. Energy is needed here because both 
sodium and potassium are moved against concentration gradients (11, 20). 
In the resting myocardial cell, the sarcolemma is more permeable to 
+ the potassium ion, so K has a tendency to move out of the cell down its 
concentration gradient. As these ions pass out of a cell, a positive 
charge is carried to the outside of the cell, which results in an 
electrical gradient across the sarcolemma in which the outside is posi-
tively charged (13). 
The Nernst equation can be used to describe the differences in 







= 61. 5 log ci· ( + + o ) for Na , K and a body temperature of 37 C , 
where Em is the membrane potential, R is the gas constant, T is the 
absolute temperature , Z is the valence, F is the Faraday constant and 
Co and Ci are the ion concentrations outside and inside of the cell, 
respectively (9). 
+ + + For K where [K] = 4mM and 1K]. = 140 mM, Em= -95 mV, which is 
0 l 
very close to the actual Em of -80 mV to -95 mV. Variations in [K+] , 
0 
as can occur, especially during ischemia and/or infarction can alter Em. 
For example, increasing [K+] will result in depolarization, while 
0 
decreasing [K+] will reduce Em or result in hyperpolarization. This 
0 
theoretical concept fits well until [K+] gets < 3mM, when the predicted 
0 
hyperpolarization is greater than the actual Em. The reason is that as 
[K+] < 3mM, sodium diffusion into the cell becomes more important in 
0 
determining membrane potential (background sodium current) (10). 
Phase 0 - Upstroke. As a depolarization occurs the myocardial cell 
+ + changes its permeability to Na and K . In the presence of the back-
6 
ground sodium current, potassium conductance decreases. Should the stimulus 
result in the threshold potential being reached, a regenerative current is 
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established. Depolarization during the upstroke of the action potential 
in most regions of the heart is determined largely by the rate of diffusion 
of sodium ions across the sarcolemma, creating the fast inward current (11). 
A decrease in the membrane permeability to potassium also contributes sig-
nificantly to the upstroke of the action potential (9). According to 
the Nernst equation for sodium, a positive membrane potential of +41 mv 
would be predicted based on a 140 mM sodium concentration in the extra-
cellular fluid and a 30 mM concentration in the intracellular fluid 
space: 
140 (Co) o 
Em = 61.5 log '""'3'0 (Ci) or 37 C body temperature 
The positive potential of +41 mM is not reached, however, due to a re-
sidual permeability to potassium and chloride (10). 
The dependence of the upstroke on the fast inward sodium channel is 
demonstrated when tetrodotoxin (TTX), a poison from Japanese puffer fish, 
is applied to the cell. As a selective inhibitor of the sodium channel, 
TTX abolishes this current (13). The premise that sodium is the ion involv-
ed, can be established by replacing the perfusing medium sodium with an 
impermeant ion like choline - the sodium current does not appear (10). 
Just as the activation of the sodium channels is a rapid process, clo-
sure of these channels is also a rapid process. Although both of these 
processes occur with extreme rapidity, recovery of these channels or the 
ability to be reactivated is much slower and not only depends on the mem-
brane voltage level but on the time elapsed from the preceding action poten-
tial (10). 
That the recovery or ability of the cell to respond to a second ac-
tion potential can be seen to be voltage dependent, can be demonstrated by 
changing the level of the resting membrane potential prior to stimulation. 
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If this resting membrane potential is high (-90 mV) rapid depolarization 
causes the sodium channel to open rapidly and widely. If, however, the 
membrane is already in a partially depolarized state, (-80 mV to -70 mV), 
then a similar stimulus produces a more slowly rising action potential. 
The amplitude and Vmax are less because the sodium shannels open less 
widely. It may also be thought of as a voltage dependent reduction in the 
available sodium carrier (10). Recovery can take up to 100 msec and can 
be prolonged by prior depolarization and drugs, such as quinidine (10). 
Another current involved in this initial phase is an outward potas-
sium current. In neurons, potassium conductance is high immediately 
following depolarization, allowing positive charges to be carried out of 
the cell initiating repolarization. In cardiac cells, however, potas-
sium conductance decreases. This tends to keep the cell in a depolarized 
state, by preventing the positive ions from repolarizing the cells. 
This is known as anomalous rectification (14). 
Phase 1 - Early Repolarization. Following the upstroke of the action 
potential there is a brief period of rapid repolarization often called phase 
1 of the action potential. This early repolarization is due mainly to a 
fall in conductance to sodium (10). 
Phase 2 - Plateau. The plateau is characterized by a steady membrane 
potential at or near zero for well over 100 msec. It is generally accepted 
that there are at least two, and possibly three, ionic currents respon-
sible for the plateau phase of cardiac muscle action potentials. The ions 
responsible for these currents are sodium and calcium and the currents 
generated are known as slow inward currents (I .) (15). 
Sl · 
The slow inward sodium channel is kinetically and pharmacologically 
9 
distinct from the fast inward sodium channel (11, 13). It has a less nega-
tive activation potential (-35 mV) and a lower inactivation potential. 
The contribution of sodium ions to the action potential differs among a-
trial, ventricular and Purkinje fibers and varies between species (11). 
For example, in ventricular muscle of the dog and cat, changing the sodium 
concentration does not greatly affect the slow inward current (17, 18). 
However, in Purkinje and ventricular fibers of the guinea pig (19, 20), the 
cow (84) and the rat, the slow sodium current plays a significant role. 
The slow inward calcium curr'ent has a threshold of -55 mV, is time and 
voltage dependent and has its maximum effect at -10 mV. Separate conduc-
tion pathways for the calcium and sodium ions are indicated by the evidence 
++ manganese and lanthanum ions preferentially block the Ca channels (22). 
A third slow inward current is a sodium/calcium slow channel. In this 
instance some bound sodium is required for this channel to be operative 
(13). 
The role of the calcium that enters the cell during the slow inward cur-
rent is involved in the release of intracellular calcium stores from the 
sarcoplasmic reticulum. It is this calcium which interacts with the myo-
fibrillar protein, troponin C, to initiate muscle contraction (9). 
Phase 3 - Repolarization. This phase of the action potential is the 
return of the Em to those levels characteristic of the resting cell. The 
ionic mechanism underlying the process is an increase in membrane permea-
bility to potassium and a decrease in sodium and calcium permeability to 
resting values (9, 11). 
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Sinoatrial Node 
Unlike cells of the atria or the Purkinje fibers, the nodal cells 
do not have a stable membrane potential. Instead, nodal cells demon-
strate spontaneous depolarization (10). 
As in the Purkinje cell, there are currents in the sinoatrial node 
that are time and voltage dependent. The characteristics of the sino-
atrial node action potential are its Em threshold ~ -35 V/sec (compared to 
80-300 V/sec for atrial fibers) (10). 
The mechanism(s) responsible for the spontaneous depolarization of 
nodal cells may be a decreasing outward K+ current, an increase in the 
r'ackground sodium current, or an increase in the slow inward calcium 
current (9). The most recent view of spontaneous depolarization is that 
it is a result of an increase in the calcium current with a subsequent 
decrease in the potassium current (15). At threshold there is a further 
increase in the permeability of the membrane to calcium and a decrease in 
membrane permeability to potassium. Sodium ions to not seem to play an 
important role in either spontaneous depolarization or in phase 0 of 
the action potential. These conclusions are based on the results ob-
tained after using pharmacological agents such as Verapamil and tetrode-
toxin (TTX) (23, 14). Verapamil, a slow calcium channel inhibitor, will 
suppress phase 0 of the sinus node, while TTX has a minor effect of sup-
pressing phase 0 of the sinus node action potential (11). Finally, de-
creasing [Na+] will not decrease the slope of spontaneous depolarization, 
0 
as occurs in Purkinje fibers. Repolarization of the SA node is brought 
about by a decrease in membrane permeability to calcium with an increase in 
permeability to potassium (15). 
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Atrium 
The atrial action potential is similar to the action potential of 
the Purkinje fibers except the duration is shorter. Diastolic potential 
is constant, hence, there is no pacemaker activity. Phase 0 is rapid and 
is followed by a brief phase 1. Phase 2 is abbreviated and often merges in-
to phase 3 repolarization. The terminal portion of phase 3 tends to 
return to diastole at a slower rate than in Purkinje fibers (10). 
AV Node 
The AV node, a region of slow conduction, is reflected in action 
~otentials of low amplitude and slow rate of rise. Spontaneous depolari-
zation, once thought to be prominent, is now believed to be absent in 
these fibers, so the AV node has little or no pacemaker activity. The 
resting potential is -80 mV with an overshoot amplitude of +5 to +10 
mV ( 9). 
Ventricle 
The ventricular action potential is similar to that described for 
the Purkinje fibers, although the duration and amplitude are less than 
that for the His Purkinje system. Spontaneous diastolic depolarization 
is not seen in the normal working myocardial cell (9). 
CHAPTER III 
THE ELECTROCARDIOGRAM 
The wave of electrical activation which arises in the SA node spreads 
through the heart, first through the atria and then the ventricles. This 
conduction takes place throughout cardiac muscle and is made possible by 
sites of low electrical resistance at junctional complexes between adja-
cent cardiac muscle cells known as the intercalated discs (24). 
In the atrial musculature, the conduction velocity is approximately 
0.3 m/sec and is slowed to 0.2 m/sec in the region of the AV node. This 
allows the atrial musculature to depolarize and contract before the ven-
tricles begin to depolarize. Conduction velocity is accelerated to 4 m/sec 
in the Purkinje system, until the termination of those fibers is reached, 
where velocity is again slowed to approximately 0.4 m/sec (9). 
The organization of the Purkinje fiber system varies somewhat be-
tween species. In the dog, the Purkinje system passes along the subendocar-
dial surface of the interventricular septum. Terminal branches arise with-
in the septum, prior to termination within the subendocardial musculature 
( 9). 
The first deflection of the electrocardiogram is the P wave, which 
represents atrial depolarization. No manifestation of sinoatrial nodal de-
polarization is evident for the electrical potential differences are not of 
sufficient magnitude. The duration of the P wave depends on both the size 
of the atr•ia and the conduction velocity (25). Occasionally, a wave of 
opposite polarity, low voltage and long duration follows the P wave. 
12 
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This is the atrial repolarization or atrial T wave (Ta or Tp). The action 
potential of the atria has a very short plateau, hence, repolarization (Tp) 
develops directly after the P wave (24). There is no isoelectric interval 
such as the ST segment. Spread of activation to the AV node and the delay 
of conduction is reflected in the PR segment of the ECG. The PR segment 
is that time from the end of the P wave to the next deflection from the 
baseline. This segment is isoelectric because the mass of tissue involved 
is too small to generate surface voltage (24). 
After the impulse has traversed the Purkinje fiber system, ventricu-
lar• activation begins, producing the QRS complex ·of the electrocardiogram 
(24). The amplitude of the QRS complex is much greater than that of the P 
wave due to the mass of tissue involved. The process of ventricular acti-
vation can be divided into three phases, septal activation, apical activa-
tion, then activation of the base of the heart (24). 
Following the QRS complex, the ECG returns to or near the baseline un-
til the last wave, T, is inscribed. This is the ST segment, and is a time 
when all regions of the heart are in a depolarized state. The isoelectric 
segment reflects an absence of potential difference within the ventricles 
at this time. The long duration of this segment reflects the plateau 
(phase 2) of the cardiac action potential (9, 24). 
The ST segment usually starts with a slowly rising phase, which de-
velops into the T wave. This is due to an asynchrony of fiber repolariza-
tion. The longer the plateau, the more isoelectric is ST. Any shift in 
the ST segment will reflect changes in the local properties of fibers. This 
can be either due to damage or to changes in heart rate (24). For example, 
ST is depressed at higher rates and elevated during slower heart rates. The 
repolarization of the ventricles produces the T wave and corresponds to 
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phases 2 and 3 of the cardiac action potential. The duration of the T wave 
is longer than that of the QRS complex, because repolarization is not as rap-
idly propagated as depolarization. The T wave is determined largely by 
local factors that may influence the duration of the action potentials in 
each region of the ventricles. 
Coinciding with the T wave is what is referred to as the vulnerable 
period of ventricular repolarization (9). It has been shown experimentally 
that stimulation during this time is more likely to result in lethal ventri-
cular arrhythmias. The underlying mechanism of the arrhythmias seen during 
this time is probably reentry due to slowed conduction and unidirectional 
block (see section on arr1hythmias). 
Another interval usually measured in the electrocardiogram is the 
QT duration (24). The end of the T wave represents the time whan repolari-
zation of the ventricle is completed. The QT duration must, therefore, 
depend upon the factors: the amount of asynchrony which may be calculated 
from the QRS, and the longest action potential duration of the myocardial 
fibers. The duration of the QT depends mainly on the heart rate, and also 
on the factors which may change the rate. Heating, for example, shortens 
the QT interval, whereas, an increase in sympathetic activation increases 
the QT duration (9, 24). 
Various Influences Upon the ECG 
Effects of Anoxia, Hypoxia and C02 
If the C02 of perfusing fluid is increased, leaving the electrolyte 
composition constant, the T wave is heightened. Reduction of coronary flow 
produces the same changes (26). Under severe oxygen lack, the T wave is 
15 
flattened and the ST segment is slightly depressed. The changes occur-
ring in the cellular action potential resulting in the ECG changes are a 
shortening of the action potential duration followed by a decrease in the 
resting membrane potential of the ischemic cells (24). 
Autonomic Influences 
Stimulation of the vagus nerve decreases propagation velocity, and 
therefore, lengthens the PQ and QRS duration. Vagal stimulation will short-
en QT while sympathetic stimulation lengthens this interval. The amplitude 
of the QRS is increased by vagus nerve stimulation and decreased by sympa-
thetic activation. The influence on the T wave is harder to isolate, but 
it is generally assumed that the vagus nerve augments while the sympathetic 
system depresses the T wave (11, 24). 
Ions 
The influence of ions on the heart are best exemplified by changes in 
the QRS and T wave, the QRS is prolonged in hyperkalemia whereas, in a hu-
man heart, a severe deficiency of Na+ will prolong the duration (9). The 
QT interval is rather insensitive to changes in plasma Na+, K+, Cl and 
!-!CO, although hypocalcemia will prolong the interval (9). Hypercalcemia 
will prolong QT even further while if [K+] ./[K+] rises, QT may be pro-
1 0 
longed (9, 24). 
CHAPTER IV 
CARDIAC ARRHYTHMIAS 
Arrhythmias or abnormal rhythms, have been classed into three cate-
gories relating them to alterations in the physiology of the heart, and 
to certain drug effects. As with any classification scheme, the possi-
bility of overlapping causes can be expected (27, 28). 
Triggered Activity 
One of the causes of cardiac arrhythmias is known as triggered activ-
ity (29). Triggered activity is sustained by a locally evoked potential 
or from a distant action potential by after depolarization (30). Such 
activity can be initiated by acetylstrophanthidin or ouabain in Purkinje 
fibers (31). An afterde.polarization can be produced when repolarization 
results in hyperpolarization. Following the hyperpolarization, a tran-
sient diastolic depolarization occurs - a delayed afterdepolarization 
(30, 32). The amplitude of the afterdepolarization depends upon the rate 
of action potential production in the fibers. By increasing the rate and 
thus the amplitude of the afterdepolarization, threshold may be reached, 
resulting in one or a burst of impulses or triggered activity (30, 33). 
The evidence to suggest the current responsible for the afterdepolariza-
tion triggered activity is the slow inward Ca++ current is that catecho-




Automaticity is a property seen in the SA node and the rest of the 
specialized conduction tissue of the myocardium (9, 30). Since the auto-
matic firing rate of the SA node is the greatest this area suppresses the 
formation of impulses from the other cells (37). Any condition which will 
suppress the activity of the SA node or enhance activity of ectopic, or la-
tent pacemakers can result in arrhythmias (28). If the s~nus node fails 
to excite the rest of the heart, a latent pacemaker may take over pri-
mary pacemaker activity (38). An example of this occurs with strong vagus 
nerve stimulation, which will inhibit sinus node automaticity as well as 
other atrial pacemakers (39). Since vagal effects on the Purkinje system 
are minimal, spontaneous diastolic depolarization may still occur, which 
can result in impulse initiation. If the impulses arise in specialized 
atrial fibers or in Purkinje fibers with maximum diastolic potentials of 
-60 mV or greater, the response seen is that of the fast type - a response 
associated with the fast inward channel (39). If the maximum diastolic po-
tential is less than -60 mV (Em -+ 0) and arise in the AV junctional or AV 
valve leaflets (slow fibers), the response is characteristic of slow con-
duction (39). 
r::nhanced automaticity resulting in a pacemaker shift may result from 
one or two reasons. One is the enhanced activity resulting from sympathe-
tic activation (40). Since catecholamines enhance activity in all conduc-
ting fibers, and activation may not be uniform, shift of pacemaker site 
is possible (41). In situ sympathetic stimulation can result in a shift 
of pacemaker site allowing the latent pacemakers to assume primary pace-
maker function (38). These conditions can result in atrial or ventricular 
Lachycardias. 
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Pathological conditions such as infarction/ischemia can result in 
local changes in fiber automaticity (39). Evidence exists that Purkinje 
fibers and normal atrial myocardial cells depolarized to -40 mV exhibit en-
hanced automaticity under pathological conditions similar to that seen in 
ischemia/infarction. Automaticity in ventricular muscle fibers has not 
yet been shown, but depolarization as a result of injury has been pro-
duced. 
Reentry 
Lately there is an increasing body of evidence used to explain ar-
rhythmias in terms of reentry. The concept of reentry depends on the 
abnormal excitation of the heart from an impulse which does not die out 
after propagation (42). Normally, an impulse initiated from the SA node 
which excites tissue in atria and ventricles eventually will die out 
when it encounters refractory tissue. For reentry to occur, the impulse 
must remain somewhere in the heart to reexcite after the refractory period. 
Since the refractory period can be as long as 500 msec, the reentry im-
pulse must remain for this period within a pathway functionally isolated 
from the rest of the heart (43). Because the conduction velocity of the 
impulses in atrial or ventricular tissue is between 0.5 to 4 msec, a func-
tional pathway could not exist in the heart to allow this to occur. The 
reentrant impulse must conduct at a slow velocity, which would not need 
a long conduction pathway (44). For example, a velocity of 0.02 msec would 
only use a pathway of 6 mm in a refractory period of 300 msec. Other mech-
anisms that would result in reentry are shortening of the refractory period, 
or re-excitation due to heterogeneities in refractory period in adjacent 
fibers. Such an example would exist in catecholamine administration or 
halothane anesthesia (42). 
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Reentry Due to Slow Conduction and Unidirectional 
Block 
Functional pathways do exist in the ventricles which will allow re-
entry in the presence of slowed conduction. Reentrant pathways can 
exist in the areas where Purkinje fibers are in loops - areas of con-
tact with other Purkinje fiber bundles and areas in contact with the 
ventricular myocardium (29, 42). Under normal circumstances, an impulse 
initiated from the SA node will invade the Purkinje system and ventricular 
muscle and then die out after encountering refractory tissue. For reen-
try to occur in the ventricle, an area of slowed conduction and unidirec-
-Honal block must exist (42). The concept of unidirectional block is 
important in reentry phenomena and implies that conduction is blocked 
completely in one direction. The mechanism of unidirectional block can 
occur in any bundle of tissue which sustains an injury and results in 
an asymmetric depression in action potential amplitude and decremental 
conduction (9). This is illustrated below: 
(darker shading indicates 
a greater degree decre-
mental conduction) 
(NOTE: Wedge shaped block to indicate asymmetric pressure to myo-
cardial strand to result in asymmetric depression of cellular function). 
Assuming: In the tissue from 0-2 and 8-10, normal propagation oc-
curs and the action. potential is capable of activating up to 2 units of 
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tissue. Between 2-3, damage is enough to completely block an impulse. Be-
tween 3-8, degree of compression dictates ability to conduct impulses. 
If an action potential starts at O, it can spread to 2, then to 4 
where depressed conduction occurs. It is delayed up to point 8, where 
it emerges again as a normal action potential. An action potential start-
ing at 10, conduction starts to slow at 8 down to 6. At 6, depressed con-
duction starts until the impulse finally reaches the area of complete 
block, and goes no further. 
After the imp1Jlse leaves the area, if it encounters tissue that is 
ready to be reexcited, a premature or reentrant beat will be initiated. 
This can result in a continuous circling of impulses resulting in repeti-
tive ventricular activation. This type of unidirectional block is similar 
to the mechanism of reflection, which may occur in unbranched bundles such 
as the His bundle. 
Reentry may result from excitation by a premature impulse entering 
the conducting system. If the cells are reactivated prematurely before 
complete recovery is possible, unidirectional block and slowed conduction 
may also result. (The safety margin of conduction is lower in partially 
refractory tissue) (45, 46). 
Reentr•y Due to Summation 
Summation, or the process where two stimuli can combine to produce 
an action potential of greater amplitude, can also occur in myocardial 
tissue (42). 
In depressed cardiac fibers that demonstrate slow response action 
potentials, the degree of activation of individual current during the 
depolarization phase is dependent in part on the strength of the depolari-
zing stimulus. After a weak stimulus produces a submaximal response, 
further depolarization can result in an increased amplitude, if done 
during the initial phases of the action potential. If both ends of a 
Purkinje fiber bundle are activated simultaneously, summation may occur 
in an area of depressed conduction, resulting in an action potential of 
greater amplitude than either response along. The impulse can then be 
conducted out of a branch of the fiber system, but at a very slow velo-
city. The time it takes to get out of the depressed area, which may be 
up to 300 msec, will put this impulse in tissue whose refractory peri-
ods are over (or nearly over), thus resulting in premature beats. 
Reentry Due to Alterations in Refractoriness 
Unidirectional block and slowing of conduction resulting from lo-
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cal alterations in refractoriness of tissues can also produce reentry (45). 
In the ventricles, there is a point along the conducting branches 
which has the maximum action potential duration and refractoriness, and 
is called the gate. This gate, under normal conditions determines the 
effective refractory period for that part of the ventricular conduction 
system. Thus, when a premature impulse enters the bundle before the 
end of the effective refractory period at the gate, it will not reach ex-
citable ventricular muscle (42). 
Localized disease or ischemia can result in alteration of the re-
fractory periods of the gate or fibers in the terminal Purkinje fiber re-
gion. Conditions for reentr'y are then established for producing prema-
ture systoles. The current thought, however, relating alterations in 
refractory period to premature beats, deals with the action potential 
duration/effective refractory period ration. There is evidence that if 
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the action potential duration in one area of cardiac muscle is shorter 
than in an adjacent area, conditions are produced for a flow of depolari-
zing current (boundary current). This current flows from the area of lon-
ger action potential duration to an area of short action potential dura-
tion, which should speed up the conduction of the adjacent area (47). 
Any of the above conditions necessary for reentry can occur as a re-
sult of changes in local factors, such as acid base balance or from 
pharmacological interventions. Changes such as this include halothane 
sensitization which alters the action potential durations and refractory 
periods of the Purkinje fiber and ventricular fiber systems (48). The 
mechanism for these changes is believed to be a result of an increased 
potassium conductance (48). 
Premature Systoles 
There are various theories concerning the underlying causes of pre-
mature systoles. There is a body of evidence, however, to suggest that 
premature systoles can be explained by reentry (9). Moe (49) has 
demonstrated reentry as an underlying cause for arrhythmias of the atria 
and possibly for those occurring in the ventricles. These arrhythmias 
range from atrial flutter/fibrillation to premature ventricular depolari-
zations and ventricular tachycardia (49). Associated with premature beats 
is a classification scheme which is related to their origin and certain 
electrocardiographic changes (50). 
Classification. Supraventricular: Supraventricular premature beats 
are those beats which arise either from the atria or the region around 
the AV node. In atrial premature beats the P wave occurs earlier than 
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normal, is positive in leads II, III and aVF. The P wave is usually ab-
normal in size and/or configuration due to its discharge from an ectopic 
pacemaker. The QRS complex, however, is usually normal for the pattern of 
ventrrular activation is usually unaffected. Those beats arising from 
around the AV node or junctional region are characterized by normal or 
nearly normal QRS complexes preceded by an inverted P wave in leads II, 
III and aVF. This occurs for atrial activation is usually in a retro-
grade manner. 
Ventricular: Premature ventricular beats are those usually arising 
from the fibers of the ventricles. The ectopic focus may originate from 
any part of the ventricle, the closer to the bundle of His, the more nor-
mal the QRS-T complex. Reentry can explain many of the electrocardio-
graphic changes usually associated with premature ventricular systoles. 
Circus movements may occur in the peripheral ventricular conducting 
system, whereas, summation may occur in the peripheral Purkinje system. 
The characteristic ECG finding is a widened, slurred QRS complex. a) 
Reentry by reflection, however, may occur anywhere in the A-V conducting 
system, from the His bundle to the distal Purkinje twigs. This would re-
sult in a premature ventricular depolarization with an aberrant QRS com-
l ) 
pl ex. J This is illustrated in a and b below: 
There is general agreement that those premature depolarizations which 
have a fixed relation to the preceding P wave, are caused by the preced-
ing impulse and may be reentrant (42). 
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Reentry by circus movement or reflection, would result in a normal 
activation sequence at first. During the QRS complex and QT interval, the 
impulse would be conducting slowly in a depressed pathway. This de-
pressed conduction is silent, most likely because the wave front is 
small and travels at low velocities. Emerging from the reentrant path-
way, an abnormal QRS complex would be inscribed. The R-R' interval is, 
ther'efore, determined by the time of conduction through the pathway. 
Fixed coupling would occur if the pathway is fixed and conduction always 
occurs at the same speed (42, 45). 
Reentry by summation also may be predicted to be characterized by 
fixed coupling if certain assumptions are made •. These include a constant 
conduction velocity of the summating and summated impulses, as well as 
a constant time for summation. These constant interval beats are known 
as unifocal ectopic beats, those arising from one ectopic focus. When 
these intervals vary and the forms vary, they are identified as multi-
focal. c) This is illustrated in c below: 
c) 
Premature beats may occur in groups of 2 or more, each resulting from 
continuation of conduction through a reentrant loop. Two are referred 
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to as a pair, three as a run and four or more as a tachycardia (50). ~~­
setting of the cardiac rhythm or a compensatory pause between is also 
usually associated with premature systoles. Although the sinus node con-
tinues at its normal rate, it encounters refractory AV nodal tissue dur-
ing the premature contraction. This refractory state of the AV node re-
sults from a partial but incomplete retrograde conduction from the 
premature ventricular contraction. Thus, although the P waves are 
occurring at their normal rates, the P wave that may precede the prema-
ture contraction is unrelated to the abnormal QRST complex. 
Occurrence of premature contractions is dependent upon origin of 
ectopic pacemakers. Whereas atrial ectopic beats rarely occur in a normal 
dog, ventricular premature contractions may occur as a result of stress 
or anxiety. Detweiler et al. (12) considers presence of premature 
ventricular contractions as pathologic. 
Hemodynamics. Cardiac arrhythmias pose their threat to life when 
they involve disturbances in the hemodynamics of circulation. The ex-
tent of hemodynamic disturbance in any arrhythmia depends upon the 
prematurity, frequency and site of origin of the ectopic impulses (51). 
Postextrasystolic Potentiation. The first beat to occur after a 
pause from a premature beat may show an increased contractility. This is 
manifested as an augmented stroke volume with a shorter period of 
isometric contraction. It has been held that the degree of potentiation 
is related to the degree of prematurity of the ectopic beat and the 
strength of the nonpotentiated contractions. 
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Frequency of Premature Beats. Only those occurring in couples or 
groups will significantly reduce the cardiac output. Ventricular pre-
mature beats may reduce the stroke volume by as much as 25 percent. The 
hemodynamic effects of PVC's depend upon several factors, the most im-
portant being the degree of prematurity. These beats are less effective 
than normal sinus beats, because being premature, the ventricles are not 
completely filled with blood at this time. One important point is that 
the energy expenditure of premature beats is not decreased to the same 
extent as the decrease in work. Therefore, their frequent occurrence low-
ers the efficiency of the heart and may lead to heart failure. 
Data obtained in dogs indicate that coronary blood flow is reduced 
about 12 percent by premature contractions. A reduction of as much as 
25 percent may occur if the frequency is increased. This in turn con-
tributes to impaired ventricular performance during these arrhythmias. 
CHAPTER V 
HALOTHANE 
In the 1950's, a series of nonexplosive, fluorinated hydrocarbon 
anesthetics were developed. Among these is halothane, an anesthetic 
that is in widespread use today in veterinary and human medicine (52). 
The effects of halothane, as with some other general anesthetics, upon the 
cardiovascular and respiratory systems is a dose dependent depression of 
a number of functions. The literature concerning these effects is exten-
sive and conclusions are variable among authors, though many investiga-
tors relate a depression of these systems with increasing alveolar 
anesthetic gas concentrations (53-59). 
Generally, halothane anesthesia results in relaxation of vascular 
smooth muscle and a decrease in myocardial contractility (60). These 
influences are presumably mediated by direct effects of the anesthetic 
on the muscle, although mediation through neural and humoral mechanisms 
remains a possibility. The evidence is that some effect on the regula-
tory mechanisms is present, but the data is difficult to interpret clear-
ly. for example, evidence favoring a direct action is the hypotension 
which results when halothane is administered to the body of a dog in a 
cross circulation preparation. If halothane is administered only to 
the head, the resting arterial pressures are changed only slightly (61, 
62). Halothane has also been shown to result in vasodilatation when ap-
plied to strips of aorta, probably working through increasing levels of 
cyclic AMP (3). 
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The effects on respiration are also disputed, these disputes being 
due in part to lack of effective experimental controls. The primary 
effect of halothane, as with most inhalation anesthetics, is respiratory 
depression (53, 54). In studies in various animals, it has been found 
that Paco2 usually rises, the extent of the rise depending on the type of 
premedication, and whether there is controlled or spontaneous ventilation 
(63-65). In man and in dogs (55, 64) an improvement in cardiovascular 
performance was associated with spontaneous ventilation, and attributed 
to lack of positive thoracic pressure, or more likely, an increased Paco2 
(55, 65). In dogs, the Paco2 did not exceed 40 mmHg, except when the 
halothane concentration was three times minimum alveolar concentration. 
Halothane Anesthesia and Cardiac Arrhythmias 
It has been well documented from the original study in 1956 by 
Raventos (52), that halothane anesthesia can result in cardiac arrhythmias. 
There are a number of factors which can result in arrhythmias, ranging from 
changes in cardiovascular system parameters such as blood pressure to the 
electrophysiology of the heart. 
One of the factors implicated in the genesis of arrhythmias during 
anesthesia is surgical manipulation (66). Another factor implicated in 
the genesis of arrhythmias is the Paco2 . As mentioned previously, with 
spontaneous ventilation, there is generally a higher Paco2 than if venti-
lation was controlled (64, 65, 67). What is important about the Paco2 is 
that there is apparently a threshold, dependent upon the anesthetic used, 
which would allow the production of arrhythmias (67). The mechanism has 
been debated, with direct CNS stimulation as one possible cause and the 
release of endogenous catecholamines as the alternative (23). Comparing 
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the effects of various anesthetics it was found that with pentobarbital 
raising the Paco2 and allowing the pH to fall to values around 7.0, 
provides protection against epinephrine induced arrhythmias. This re-
sult is in agreement with those found with cyclopropane in dogs (67). 
This protection is dependent upon maintenance of a state of acidosis, for 
if arterial pH was kept constant, protection was not afforded. Artifi-
cially increasing H+ concentration in animals via acid infusions, was 
found to protect against epinephrine induced arrhythmias in spite of a nor-
mal end tidal Paco2 . The proposed mechanism(s) for protection might in-
clude: 1) a reduced vasopressor response to systemically administered 
catecholamines during acidosis and/or 2) a direct inhibition of metabolism 
during acidosis (67). 
Other investigators have found a threshold for Paco2 induced 
arrhythmias during anesthesia. With cyclopropane, for example, the 
threshold Paco2 varied from 44mm to 72mm of mercury, depending upon the 
anesthetic concentration. For halothane, the Paco2 threshold ranges from 
60mrn to 140rnrn of mercury (66). 
Role of HeaFt Rate and Blood Pressure 
It has been documented by various investigators that change in heart 
rate and blood pressure.play a role in the genesis of arrhythmias (1). 
The response to epinephrine generally consists of an immediate presser 
effect with an increase of heart rate, followed by a depressor effect, 
widening of pulse pressure and a decrease in heart rate (68, 69). 
It was reasoned since the first studies relating cardiac arrhythmias 
with blood pressure under chloroform, that a change in aortic pressure 
was at least one of the criteria necessary for production of ventricular 
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extrasystoles (66). It was later found, that this change, although not ab-
solutely necessary, would facilitate the production of the arrhythmia. 
Moe et al. (70) reasoned that blood pressure, heart rate and the sympatho-
mimetic amines in some combination were important factors. Heart rate is 
also an important factor in arrhythmia production. Vick and Dresel have 
found that cardiac arrhythmias produced by epinephrine infusion could be 
terminated by vagal stimulation (71). If a lower infusion rate was used, 
but the atria were paced at the higher rate, arrhythmias appeared. 
Halothane acts on the sinoatrial node to produce a slower rate of 
rise on the phase 4 spontaneous depolarizati~n and a decreased overshoot 
amplitude. This is manifested as a slower sinus rhythm and thus heart 
rate (48): Halothane also depresses conduction velocity, which is manifes-
ted by increased interval duration of the surface electrocardiogram (72). 
In the Purkinje and ventricular fiber systems, halothane results in a de-
crease in the Vmax, overshoot amplitude and action potential duration (48). 
The effective refractory period is also shortened in these areas, but 
not to the same extent (73, 74). 
Considering the experimental evidence, the production of arrhythmias 
by halothane. is most likely due to reentry of impulses and not from en-
hanced automaticity (75). Reentry requires a slowed conduction and/or un-
equal distribution of effect on the refractory period (29, 73). These 
conclusions come from experiments on ouabain toxicity and ventricular 
escape time (75). It was found that when ventricular tachycardia was in-
duced in dogs with ouabain, halothane exposure converted this to sinus 
rhythm. In the same experiments, strong vagal stimulation produced 
cardiac standstill. Vagal escape time and rate of the escape beats was 
lower in dogs anesthetized with halothane than in dogs anesthetized with 




The influences of the sympathetic nervous system are attributable to 
many of the problems seen in cardiac arrhythmias. 
Innervation 
The innervation of the heart is supplied by thoracic nerves, T1 -T 5 , 
whose postganglionic fibers richly innervate the sinus and AV nodes. 
Adrenergic innervation of the atrial musculature is also quite extensive, 
though not to the same extent as in the nodal areas (33). Ventricular in-
nervation is also extensive, but the density of the innervation varies 
markedly in different regions. The Purkinje network appears to have only 
limited innervation (22). 
B Receptor Activation 
It was postulated in 1906 that the catecholamines released from the 
nerve terminals, reacted with a receptor to result in a physiological 
effect (76). Since then, these receptors have been classified as a and 8 
and attempts to encompass all known effects have been made (77). When 
dealing with the cardiovascular system, a receptor stimulation results 
in arteriolar constriction and little direct effect on the heart. There is 
not much evidence to suggest a receptors exist in the heart resulting in 
a decreased heart rate and decreased contractility (38). Beta receptor 
stimulation results in arteriolar vasodilation, with an increased heart 
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rate, strength of contraction and conduction velocity. The density of 
the beta receptor has been the subject of many investigations (78). It 
has been suggested that the B receptor has protein binding sites with cru-
cial sulfhydryl groups, located on the outer membrane surface (38). 
Activation of S receptors by epinephrine results in a series of 
reactions eventually leading to the physiological response. Studies 
indicate that the formation of cyclic AMP may be the link between S re-
ceptor stimulations and the physiological response (79). Beta receptor 
stimulation has been shown to increase the activity of the membrane bound 
enzyme, adenylate cyclase, which in turn catalyzes the formation of 
cyclic AMP from ATP. Beta receptor antagonists such as propranolol can 
block its activation (80, 81). 
Electrophysiology 
The catecholamines, whether endogenous or exogenous, elicit a wide 
variety of effects depending upon the types of cardiac muscle fiber 
studied. 
Sinus Node 
The sinoatrial node exhibits spontaneous phase 4 depolarization and 
by changing the slope of depolarization, the rate of firing will change 
( 1). 
Catecholamines increase the slope of phase 4 depolarization and 
therefore, shorten the cycle length between spontaneous action poten-
tials (38). The primary effect of catecholamines is to enhance inward 
calcium current (38). Calcium influx is also enhanced by shifting the 
threshold potential for the current to more negative levels (82, 83, 84). 
34 
A secondary effect of catecholamines is to accelerate deactivation of the 
outward potassium current which is responsible for repolarization (38, 9, 
73). The electrophysiological effects are an increased Vmax and over-
shoot amplitude of the action potential (38). 
Purkinje Fibers 
Beta receptor stimulation enhances the spontaneous depolarization 
seen in Purkinje cells (38). Overall effects of catecholamines on the 
Purkinje fiber system include an acceleration of repolarization with a 
shor'ter action potential duration. The frequency of spontaneous depolari-
zation is increased, with no direct effect on phase 0 (9, 38). The 
plateau phase of the action potential is also increased to a more posi-
tive value (85). Enhancement of spontaneous depolarization is thought to 
be due to an increase in the slow inward calcium current, with a shift in 
the threshold potential to more negative levels (9, 82, 83). Evidence 
suggests this may also be mediated by cyclic AMP (86). As in nodal fibers 
there is no effect on the rapid inward sodium current, neither increasing 
the current nor altering the threshold potential (9, 73). Catecholamines 
also cause a more rapid and complete deactivation of the outward 
potassium current in Purkinje fibers (73). 
Atrium 
Beta receptor stimulation has little effect on the action potential 
of the normal working atrial myocardium (38, 87). Repolarization may be 
accelerated in some species (dog, cat) but not in others (rabbit, guinea 
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pig, rat) (88). No effect is seen on Vma.x in normal cells (38). In some 
specialized atrial fibers, spontaneous depolarization may be induced or 
enhanced (89). 
AV Node 
Beta receptor stimulation of the AV node improves speed of and 
increases Vmax in the cells of the upper and middle nodal regions. There 
appears to be no effect on the cells of the lower nodal region (9, 38). 
Ventricle 
There are very few effects of neurogenic amines on resting membrane 
potential of ventricular muscle, Vmax of phase 0 or the overshoot ampli-
tude of the spike potential (38, 41). Repolarization may be either slight-
ly prolonged or accelerated, while spontaneous diastolic depolari~ation 
is not enhanced. The effects result in shortening of the relative re-
fractory period (38, 41, 90). 
Electrocardiographic Changes 
The increased conduction velocity in the AV node is manifested as a 
shortening of the PR interval in the ECG (38, 91). Changes in the ST seg-
ment and T wave are also seen, probably resulting from variations in the 
ventricular muscle action potential (38, 92). 
Arrhythmias due to enchanced automaticity may occur in response to 
catecholamines (29). This is usually manifested in an increased firing of 
the sinus node resulting in tachycardia. By the increased rate, the 
sinus node can control initiation of ectopic pacemakers in the atria or 
ventricles. This is true in normal canine hearts, where the Purkinje 
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fibers rarely initiate impulses greater than 80-100 per minute ~fter 
maximum activation. However, in infarcted tissue, the response may be 
higher, thus initiating and sustaining ventricular ectopic beats (29, 39). 
Several mechanisms are proposed for catecholamine effects on the 
heart which will result in reentry of impulses (29, 42, 80). These 
effects are manifested by changes in the refractory period, particularly 
of the ventricular fibers. With the nonuniform distribution of nerve fi-
bers on the ventricular muscle, a disparity of the spread of effect and of 
ventricular recovery can occur, leading to reentry. These conditions can 
be potentiated in instances where a nonuniform recovery of cells already 
exists, such as in myocardial ischemia or in subjects anesthetized 
(exposed) with halothane (73, 93). Slow response action potential develop-
ment can also be envisioned in extensive myocardial damage, where [K+] 
0 
may obtain levels which result in complete inactivation of the fast 
sodium channel (93). 
CHAPTER VII 
ACETYLCHOLINE 
The effects of the neurotransmitter, acetylcholine, on the nodal 
cells and Purkinje cells are related to its effects on the ionic cur-
rents (9, 15). 
Sinus Node 
The greatest effect of the parasympathetic neurotransmitter is on 
the SA and AV nodes (41). The effects of acetylcholine on the SA node is 
a decrease in calcium influx along with an increase in the potassium con-
ductance (94-97, 98). This is manifested as prolongation of the effective 
refractory period (9, 99), hyperpolarization and a slowing of the rate 
of closure of potassium channels. Inhibition of the release of nor-
epinephrine from sympathetic nerve terminals and an increase of cyclic 
GMP are the probable mechanisms of acetylcholine's actions (22, 100-102). 
Atrial contractility is decreased as well by acetylcholine application and 
the increase in cyclic GMP (2, 103). Through the cyclic GMP mechanism, 
it has been shown acetylcholine can antagonize the effects of the 
catecholamine, isoproteranol (101). Under conditions of low resting 
potassium conductance, acetylcholine tends to hyperpolarize the cells 
increasing Vmax and the amplitude of the action potential (9). Vagal stim-
ulation has the potential of inducing atrial arrhythmias due to an unequal 




Acetylcholine has little or no effect on the His Purkinje system or 
the ventricles. High concentrations can shorten action potential dura-
tion, again possibly due to increased potassium conductance (9, 15). 
AV Node 
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Acetylcholine is known to slow conduction in the AV node, in the AN 
and N (upper nodal and nodal) regions. Repolarization is accelerated and 
the amplitude of the action potential may be reduced (9). 
CHAPTER VIII 
LIDOCAINE 
Lidocaine hydrochloride, a local anesthetic, is a widely used drug 
for use in the treatment of ventricular arrhythmias (104-106). On the 
studies of lidocaine as a local anesthetic or antiarrhythmic, its quar-
ternary derivatives, QX314 and QX572 are extensively used because of their 
permanent positive charge at body pH (6). 
The mode of action on nerve or myocardial cells is believed to be 
exerted on the fast sodium channels, which control the influx of sodium 
ions (4, 107). Evidence for this is derived from its application to the 
nerve or cardiac cell membrane, resulting in a decrease in Vmax (or the 
rate of rise of the action potential) which is primarily controlled by 
fast sodium influx (106, 108, 109). More specifically, the effects of the 
local anesthetic appears to be on the 'inactivation' aspect of sodium per-
meability (4, 109). Evidence indicates that anesthetic molecules combine 
with 'open' sodium channels, delaying closure as well as reactivation of 
these channels (4, 109). 
As an antiarrhythmic agent, lidocaine's effectiveness depends on 
its effects upon conduction, refractoriness and automaticity of cardiac 
fibers (106). Lidocaine was first used as an antiarrhythmic in 1950 by 
Southwirth (110). Although not very effective in the treatment of supra-
ventricular arrhythmias, it seems to be the drug of choice in the treat-
ment of ventricular arrhythmias (106). There appear to be conflicting 
views as to the effects of lidocaine on the cardiac action potential. 
3 <) 
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According to Bigger and Mandel, there is little or no effect on action po-
tential Vmax until toxic concentrations and it speeds conduction across the 
papillary muscle - Purkinje fiber junction (108). Singh and Vaughan-
Williams (111), however, have reported that lidocaine in concentrations 
less than 10 µg/ml has a myocardial depressant effect. It should be noted 
that these depressant effects are dependent upon [K+] 0 , being more pro-
minent as [K+] was increased. These depressant effects were similarly 
0 
noted by Rosen, Merker and Pippenger (2). Rosen et al. (2) showed that 
with lidocaine infusion, there was a decrease in action potential ampli-
tude and Vmax, with an acceleration of repolarization in Purkinje fibers. 
The voltage time course of repolarization is accelerated as ~ result of 
the effect on phases 2 and 3 of the action potential. Below therapeutic 
concentrations of 1 µg/ml, control action potential parameters were again 
attained (5, 112). 
Effect on Action Potential Duration, Refractoriness 
and Conduction of Premature Impulses 
Lidocaine shortens the action potential duration and effective re-
fractor·y period of Purkin-je fibers (109) 1 the magnitude of effect is 
dependent upon the location of the fiber (113). Lidocaine shortens 
these parameters in the fibers whose action potential duration is the 
longest (106). 
Effects on Automaticity 
Lidocaine suppr•esses spontaneous diastolic depolarizations and au-
tomatic impulse initiation which occurs at membrane potentials between 
-90mv and -60mv (106). At normal therapeutic concentrations, there is no 
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effect on impulse initiation by the sinus node, so the latter may be re-
stored as the dominant pacemaker (114, 115). Effects of lidocaine on 
those potentials occurring at -60 mv (slow wave potentials) are uncer-
tain. Evidence, however, indicates that when the membrane potential is 
-60 mv, the phase 4 spontaneous depolarization is quite resistant to li-
docaine (106). This may be, in part, why some ventricular arrhythmias are 
not abolished by lidocaine (116). 
Ionic Basis of Effect 
Phase 0 
The effect on this phase of the action potential has been attribu-
ted to changes in the time dependent activation of the sodium channels. 
As a result, action potential amplitude and Vmax are decreased (117). 




Lidocaine modifies phase 4 of the action potential by changing the 
outward potassium current which is initiated when the diastolic potential 
is restored (106). Phase 4 depends, in part, upon the outward potassium 
current, which is increased in the presence of lidocaine (5). This leads 
to a slower rate of depolarization and slower impulse initiation in ec-
topic pacemakers (106). This effect on various heart tissues may be rela-
ted to lidocaine's ability to result in a potassium efflux when applied 
to the tissue (106). Kabel (116) showed that lidocaine resulted in a lar-
+ ger K efflux from Purkinje and ventricular fibers than from atrial fibers. 
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The basis for this difference is unknown but it may be due to the nature 
of the action potential itself in these tissues (116) and the role of the 
potassium current in the generation of spontaneous depolarization (118). 
Anomalous rectification occurs in all of the tissues studied but at pre-
sent there is insufficient knowledge of the process to obtain significance 
(119). 
Phase 2 and Phase 3 
When lidocaine is added to the superfusate, the voltage level of 
phase 2 becomes more negative and action potential duration was decreased 
(6). Although the effect is more marked, addition of the derivative had 
similar effects (6, 109). 
The possible mechanism of lidocaine's effect on the phase 2 plateau 
voltages can be interaction from within the membrane on the secondary in-
ward current (isi) or interaction with the repolarizing potassium current. 
It should be noted that the effect on action potential does not correspond 
well with the potassium efflux in ventricular and Purkinje fibers (108, 
114). The action potential durations of Purkinje fibers are shortened to 
a greater extent than fibers of the ventricle, yet potassium efflux is 
greater in the ventricle (108). A correspondence is not necessarily 
expected since the ionic currents in the tissues may not carry the same 
significance (114). 
Basis of Antiarrhythmic Action 
The effectiveness of lidocaine as an antiarrhythmic agent depends 
upon its modification of action potential duration and effective refrac-
tory period (106). 
43 
The effects upon the action potential duration/effective refractory 
period and conduction velocity are seen best in examples of ischemic or 
infarcted tissue (47, 106). In these tissues, the pH is likely to be low-
er from acidosis, anoxia or metabolites and the [K+] is likely to be 
0 
higher (120, 121). Action potential duration is shorter in infarcted 
tissue due in part to an increase in potassium conductance related to 
the local elevated potassium concentration (121). In normal fibers, the 
action potential duration is shortened in response to lidocaine, also 
thought to be related to an increased potass~um conductance (109). The 
I 
selective depression of conduction velocity in damaged tissues can be 
related to the pH and ionic effects (4, 107, 112). Thus, in ischemic or 
infarcted tissue with partially depolarized cells, lidocaine has a greater 
depressant effect on conduction velocity. By further slowing reentrant im-
pulses, which are usually already slowed, lidocaine can thus create a bi-
directional block, where once existed a one-way block. The effects of 
lidocaine on the effective refractory period may be related to the recov-
ery kinetics of the rapid inward current. Lidocaine delays the time for 
recovery of the channels for i , thus delaying the time during and after 
na 
the action potential when a new action potential may be initiated. The 
refractory period is thus prolonged relative to the action potential dura-
tion (~APD/ERP ratio). By slowing the time dependent recovery lidocaine 
might be expected to have little effect on slow or normal heart rates. A 
way that disparity of action potential duration/effective refractory pe-
riod may result in reentry is through the development of boundary currents 
(120). The shorter action potential duration in the ischemic zone sets 
up a potential difference with a flow of depolarizing current from the 
normal to the ischemic zone. The slow conduction in the ischemic zone 
enhances this mechanism. By decreasing action potential duration in 
only the normal tissue, the action potential durations in both zones 
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are nearly equal, diminishing the differences in potential in the latter 
part of the action potential. By increasing effective refractory period 
to a greater extent in the ischemic zone any current would encounter re-
fractory tissue and would less likely propagate. This may be the mechanism 
in lidocaine's ability to raise the arrhythmia threshold dose of epine-
phrine under halothane. By decreasing the disparity in action potential 
duration between fibers induced by halothane, the heart is thus protected 
(this effect is present despite the observation that lidocaine decreases · 
conduction further in the presence of halothane). Although it might be 
expected, it has been reported that there is no evidence of electrocardio-
graphic changes of P-R, QRS, QT or R-R intervals (104). This may not be 
expected due to lidocaine's effect on conduction. These conduction 
changes may not be of sufficient magnitude to be apparent in the surface 
ECG (104). 
CHAPTER IX 
XYLAZINE (ROMPUN R) 
In 1962, in Germany, Bayer A.G. Leverkusen (122) synthesized a new 
drug to be used in the chemical restraint of horses, xylazine hydrochlor-
ide. Chemically it is (2-(2,6 dimethyl phenylamino) -4-H-5,6 dihydro 1,3 
thiazine) and is used today as a sedative preanesthetic, analgesic and 
muscle relaxant (123-125). The pharmacology of uptake and excretion has 
not yet been reported for large animals, but results have been obtained 
for rats by Duhn et al. (126). It was found that following an intravenous 
injection the drug was distributed to the central nervous system, kidneys, 
pancreas, liver and thyroid. Seventy percent of the dose was excreted in 
the urine with 8% in the unchanged form. The remainder was excreted in 
the bile, with excretion being completed within 10-15 hours. Follow-
ing I.M. administration, within 10 minutes, 67 percent of the dose was 
absorbed with free and conjugated metabolites excreted in the urine (127). 
Peak excretion took place within 2 hours and the drug was undetectable 
after 10 hours. Xylazine administration is associated with various 
changes in hematologic and blood chemistry parameters (122). Within 
the first hour postinjection, blood glucose increases while plasma insulin, 
RBC, PCV and Hb parameters fall. All levels return to normal within 24 
hours (128, 129). 
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Cardiorespiratory Changes 
Following administration of xylazine to animals, several changes 
occur in the cardiovascular and respiratory systems which must be con-
sidered when using this agent as a preanesthetic. 
The effects of xylazine on respiration have been investigated by 
several authors with the overall conclusion that no significant changes 
occur (130, 131). 
In sheep, blood gas values showed no significant changes in PMa, 
Paco2 , or Pao2 , except in two cases where a slight increase in Paco2 
occurred following a 3-5 minute period of apnea (130). 
46 
The initial cardiovascular event seen with administration (IM or IV) 
is a presser response, accompanied by increases in both heart rate and 
myocardial contractility (132). This sympathomimetic response lasts for 
1-3 minutes and is followed by a longer period (up to 60 minutes) of 
hypotension, bradycardia and fall in cardiac output. This period is 
accompanied by an increase in sensitivity of the baroreceptors to changes 
.:inblood pressure (133). The initial sympathomimetic phase has been attri-
buted to a few possible factors. One is central stimulation of the cardiac 
nerves, as determined by monitoring the splanchnic and cardiac nerves 
(68, 133). Another is the release of catecholamines, since after adrenal-
ectomy, the blood pressure response will be decreased by 50% or more (68, 
134). The other possibility is the Anrep effect, which attributes the 
increased cardiac contractility to an increased end diastolic ventricular 
fiber stretch resulting from an increased arterial pressure (135). Evi-
dence for this last hypothesis comes from pharmacological studies using 
a and 8 blocking agents, phentolamine and propranolol. In those animals 
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treated with phentolamine, the hypertensive phase was decreased, while in 
those treated with propranolol, the hypertensive phase was potentiated and 
the subsequent hypotension was reduced (7). Evidence suggests possible a 
and f3 receptor activity. The a agonist activity has been related to its 
ability to contract rabbit atria, guinea pig vas deferens,and the cat nic-
titating membrane (7). The decrease in blood pressure is associated.with 
decreased aortic flow, even in the presence of an increased peripheral 
resistance (134). Xylazine has also been shown to depress contractions in 
guinea pig atria, which is not abolished by atropine, phentolamine, propra-
nolol or hexamethonium (7). 
That xylazine results in changes in conduction is evidenced by the 
presence of cardiac arrhythmias such as atrioventricular conduction block, 
especially prominent in horses (69, 125). It was also shown to-be 
present in dogs after administration of atropine, casting some doubt on 
their origin as being due to an increased vagal tone (134). One possi-
bility is that xylazine is acting on the heart as a local anesthetic -
membrane stabilizing agent (7). As mentioned previously, those anti-
arrhythmic agents classified as local anesthetic - membrane stabilizing 
agents can result in a depressed conduction, and possibly decreased con-
tractility. That xylazine possesses a local anesthetic effect is shown 
by its effects on the neuromuscular junction and frog sciatic nerve pre-
paration. Aziz and Martin (7) showed xylazine blocked the neuromus-
cular junction in a manner similar to d-tubocurarine, yet neostigmine 
did not angatonize xylazine's effects. They also showed that a complete 
blockage of the action potential occurred with concentrations of .075% 
and higher concentrations produced a more rapid block with a longer recov-
ery time. As the blockage occurred, there was a decrease in conduction 
velocity of the compound action potential. Results similar to these 
were obtained with 0.5% procaine (7). These effects could possibly 
have a beneficial application to the protection of the heart from the 
cardiac stimulating effects of epinephrine under halothane anesthesia. 
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Muir et al. (8) have suggested, however, that the effect of xylazine 
is not to protect the heart from the arrhythmogenic properties of epine-
phrine under halothane, but enhancement of the sensitivity of the halo-
thane exposed heart to epinephrine. Data to support their hypothesis 
was obtained by comparing the effects of epinephrine in groups of dogs 
receiving xylazine/thiamylal/halothane or acetylpromazine/thiamylal/ 
halothane combinations. Although acetylpromazine allowed a greater dose 
of epinephrine to be given, the presence of thiamylal needs to be ques-
tioned in light of the evidence that thiamylal also sensitizes the heart 
to epinephrine (8). This data is in contradiction to that found by Kerr 
et al. (136), who found the use of xylazine in horses as a preanesthetic 
resulted in less respiratory depression and a greater cardiovascular sta-
bility during general anesthesia with halothane. Kerr et al., also found 
less potentiation of the cardiovascular depression associated with halo-
thane. There were differences in heart rate associated with each 
treatment but these may have been due to a greater respiratory depression 
in the acetylpromazine treated animals (136). 
This thesis attempts to examine the arrhythmogenic properties of 
epinephrine in dogs under halothane anesthesia and the protection afforded 
by treatment with lidocaine or xylazine. The basic assumption in this 
study is that since lidocaine and xylazine possess structural and func-
tional similarities, their effects on the response of the myocardium to 
epinephrine would be similar. 
CHAPTER X 
MATERIALS - METHODS 
Six mongrel dogs, of both sexes (4 males, 2 females) and various 
weights (7.5 .!_ 0.8 S.E. kilograms) were obtained from the Oklahoma State 
University animal care unit. Upon arrival and for at least three con-
secutive days a lead II electrocardiogram was run for each animal to 
screen for any abnormalities. Any animal showing premature ventricular 
contractions or any ectopic rhythm was discarded from the study. Serum 
electrolytes and enzymes (SCOT, SGPT) were determined upon arrival. CBC 
and the direct test for heartworms were run on each animal for three con-
secutive days or until baseline hematological values were obtained. 
Canine distemper and rabies vaccine were also given to each dog. Daily 
body temperatures were taken and recorded. 
All animals were housed singly in cages, and fed standard laboratory 
chow and water ad libitum. Each animal was handled and brought into the 
laboratory daily for at least one week prior to experimentation. In the 
laboratory they were placed in the restraining cradle and the ECG was re-
corded. Blood values (CBC and enzymes) were determined prior to initia-
tion of the second phase of the experiment. 
NOTE: One dog (#5) was treated for pulmonary congestion with chlor-





The basic experimental design consisted of injecting various doses 
of epinephrine (2µg to 1Bµg total dose in increments of 2µg) under two 
conditions and three treatments. The conditions were either anesthetized 
with halothane or awake. The treatments were injections of lidocaine, 
xylazine or saline administered through an indwelling catheter. Drugs to 
be given were chosen on a random basis, with each dog receiving all treat-
ments. Individual trials were separated by at least 72 hours throughout 
the procedure, the lead II ECG was recorded, and the blood gases were moni-
tared. 
Drugs/instrumentation 
1 · R 
The halothane used was delivered through a Fluotec vaporizer. 
Lidocaine hydrochloride2 , without epinephrine, was given as a 4 mg/kg 
I.V. bolus followed by a 1 mg/min infusion in a saline drip. Xylazine3 
was given in a dose of 1.0 mg/kg I.V. and the saline group received a 
2 ml injection of saline. Each of these groups had a normal saline 
infusion of 1 ml/min. The epinephrine4 for injection was prepared 
daily in a 1:100,000 dilution. 5 The ECG was recorded on a polygraph , 
1 R Fluothane , Ayerst Laboratories 
2Xylazine HCl without epinephrine, Astra Pharmaceutical 
3 
Rompun HCl, Bayvet Corp., Kansas 
4Epinephrine Injection, Haver-Lockhart 
5 Grass Instruments, Model F polygraph, Quincy, Massachusetts 
while the dogs were in a cradle allowing the legs to move freely. Body 
6 temperature was maintained with a circulating hot water pad • Blood 
gases were analyzed on a Corning 175 blood gas machine7 . 
Procedure 
Group 1: Halothane 
Each animal was brought into the laboratory fifteen .minutes prior 
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to each trial. Induction of anesthesia was accomplished with a mask and 
5% halothane/25% N20/70% o2 until a surgical level of anesthesia was 
reached. After incubation was accomplished (approx. 5 minutes after 
start of anesthesia), N20 was discontinued. Thirty minutes were allowed 
to expire, with the animals breathing spontaneously, before the control 
period recordings were taken. Anesthesia was delivered through a semi-
closed rebreathing system with 1% halothane/02 during this period. Fol-
lowing this, blood gases were determined. The control period recording 
and subsequent recording periods were five minutes in duration. After 
the control time, lidocaine, xylazine or saline was injected. Five min-
utes later, bolus injections of epinephrine were given. The initial dose 
was 2µg, wit:h 2µg being added to subsequent doses until one of the fol-
lowing criteria were met: 
1. multiple ectopic ventricular beats; 
or 2. multifocal ectopic ventricular beats; 
or 3. a final dose of 13 µg/kg epinephrine; 
or 4. intervention with any drug to resuscitate the animal. 
6 Gaymar T Pump 
7cornin[J, 175 automatic pH/blood gas analyzer 
(For example, it was necessary to intervene with atropine in cases of 
cardiac arrest when heart would not respond to external massage). 
The arrhythmias were selected because of their close relationship 
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to the development of ventricular fibrillation. The dose of epinephrine 
(13µg/kg) chosen was the highest reported dose given under halothane 
anesthesia. The dogs were allowed to recover in the cradle then returned 
to their cages. 
Group 2: Awake 
The same procedure was followed as in group 1, except for the anes-
thesia. In this group the equilibration period was twenty minutes. 
Data Analysis 
Data were analyzed for heart rate and selected intervals and ampli-
tudes. (see diagram). a = p amplitude (mv) 
b = R amplitude 
c = T amplitude 
d = p duration (seconds) 
e = PR segmerit 
f = QRS interval 
g = QT interval 
Heart Eate 
Heart rate data were analyzed in 10 second intervals at -10 sec, +10 
sec, +20 sec, +30 sec, +40 sec, +50 sec, +60 sec, +2 min, +3 min, +4 min 
(e.g., +30 sec interval was +30 to +40 seconds). Waveforms were counted 
and multiplied by six. The analysis consisted of analysis of variance 
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d f . l . 8 an actor ana ys1s . 
The analysis of variance divided the data into three categories, one 
of which was the effect of the three drug treatments (lidocaine, xylazine 
or saline) on the heart rate. If there was a significant difference 
(up <.05), the computed last significant difference values were then 
used to distinguish among groups. The second analysis was determination 
of the effect of condition (anesthetized or awake) upon the heart rate. 
The third determination was a test of interaction. If a significant re-
sult appeared here, this was taken to mean under one condition the magni-
tude of effect was not parallel to that seen in the other condition. 
Each of these three categories were analyzed by dose of epinephrine, tak-
ing the time intervals into account. The results here were then utilized 
for factor analysis. 
For the amplitude and interval data the absolute numbers as well as 
the change in interval and amplitude from the control or preinjection 
values were analyzed by analysis of variance. A correlation procedure 
was then made for all the variables. 
8Data was analyzed on the Oklahoma State University computer, or 
IBM 158, using the SAS (Statistical Analysis System) package for 




The heart rate data was analyzed for differences among the three 
treatment groups (lidocaine, xylazine and saline) and the two conditions 
(anesthetized, awake) in response to individual doses of epinephrine 
(range 2µg to 18µg) and injection of the treatment drugs. Actual heart 
~ate, change and percent change in heart rate were analyzed in this manner. 
(NOTE: This procedure was followed for the interval and amplitude 
data as well.) When a significant difference was indicated between the 
treatment groups, the least significant division was used to determine 
which groups were different (all determinations significant at p <.05 
level). 
For actual heart rate, analysis of variance showed significant 
differences between treatment drugs, during the control or preinjection 
period and when epinephrine (all doses) were administered. The differen-
ces were found between 1) the lidocaine and xylazine and 2) the 
saline and xylazine groups. There was no difference between the lidocaine 
and saline groups. There was no significant drug x condition interac-
tion for the control period. There was a significant drug condition 
interaction with epinephrine administration. 
Epinephrine doses of 2µg to 18µg resulted in differences between 
all three treatment groups. Factor analysis, on the other hand, gave 
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slightly different results. First, the control or preinjection rate for 
all three groups were not significantly different. Epinephrine doses of 
2µg to 10µg and 16µg to 18µg resulted in differences between 1) the 
lidocaine and xylazine groups and 2) the xylazine and saline groups. 
There was no difference between the lidocaine and saline treatment groups. 
For epinephrine doses 12µg and 14µg, the difference was between 1) the 
lidocaine and xylazine and 2) the lidocaine and saline groups. There 
was no difference between the saline and xylazine groups. In all in-
stances, the xylazine group had the lowest mean heart rate of the three 
groups. The interaction of drug and condition after administration of 
epinephrine was a factor of nonparallel response under the awake or anes-
thetized conditions. The data was classified by drug type and epinephrine 
levels to compare the anesthetized and awake condition. The analysis of 
variance showed the difference to be significant and the results were 
similar to those found for effects of treatment, with the anesthetized 
group having the lowest mean heart rate. However, factor analysis showed 
no significant difference between conditions. 
The next analysis was on the change and the percent change in heart 
rate. Since these analyses represent a change from the preinjection time 
(time=O), any significant differences automatically include differences 
at the measured time intervals. Time intervals measured were from time=O 
or pr·einjection to +240 seconds, and were 10 seconds in duration. Analy-
sis showed that after +60 seconds there were no differences between the 
three treatments or the two conditions, p >.05. For both the change and 
percent change in heart rate, injection of xylazine slowed the heart rate 
(mean rate) to a greater extent over the 60 second time interval (p <.01) 
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4 mg/kg bolus followed by 1 mg/min infusion 
1 mg/kg I.V. followed by saline infusion 
2 ml normal saline followed by saline infusion 
Figure 1: Mean Change in Heart Rate (Beats/Minute ± Standard Error) 
following injection of Treatment Drugs. 
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For determination of significantly different groups, (p <.05), 
use the least significant difference values: 
@ 10 seconds 13.3 
@ 20 seconds 11. 9 
@ 30 seconds 14.4 
@ 40 seconds 14.1 
@ 50 seconds 15.3 





4 mg/kg bolus followed by 1 mg/min infusion 
1 mg/kg I.V. followed by saline infusion 
2 ml normal saline followed by saline infusion 
Figure 2: Mean Percent Change in Heart Rate (±Standard Error): 
Effect of Treatment Drug Injections. 
Injection of epinephrine, 2µg, resulted in an increase for change 
and per•cent change of heart rate over time for the lidocaine and saline 
groups, with a decrease in heart rate (mean change of -4.6 beats/minute) 
for the xylazine group (Figures 3 and 4). For doses of epinephrine, 8µg 
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to 14µg, differences were found between 1) the lidocaine and saline groups 
and 2) the xylazine and saline groups (p 1<.05) with no significant dif-
ference between the lidocaine and xylazine groups. Condition affected the 
heart rate (a lower mean heart rate and response for the anesthetized 
group) at all doses of epinephrine (figure 5). Factor analysis confirmed 
the results of the analysis of variance. 
Intervals 
Analysis of variance on differences between treatment groups using 
raw data, showed differences in all intervals measured (p <.01). For the 
treatments, these differences were for the P wave duration, PR segment 
duration, and QRS interval. For the P wave and PR segment duration the 
1) lidocaine and saline and 2) the xylazine and saline groups were sig-
nificantly different. The injection of lidocaine or xylazine prolonged 
these intervals with respect to the saline treatment group. For the QRS 
interval, there were differences between all three groups with the xy-
lazine group having the longest mean duration. There were no significant 
variations with respect to time. Condition affected the response, the 
anesthetized group having the longer duration (Figure 6-12). 
Injections of epinephrine (see table for actual doses) resulted in 
a decrease in mean interval duration for the lidocaine treatment groups, 
an increase in mean interval duration for the xylazine treatment group 
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4 mg/ke bolus followed by 1 mg/min infusion 
1 mg/kE I.V. followed by saline infusion 
2 ml normal saline followed by saline infusion 
Figure 3: Mean Change in Heart Rate (Beats/Minute ± Standard Error) 
in Response to 2µg Epinephrine: Effect of Treatment Drug. 
59 
MEAN PERCENT CHANGE IN HEART RATE (zSTANDARD ERROR) 
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For determination of significantly different groups (p <.05), 
use the least significant difference.values: 





4 mg/kg bolus followed by 1 mg/min infusion 
1 mg/kg I.V. followed by saline infusion 
2 ml normal saline followed by saline infusion 
Figure 4: Mean Percent Change in Heart Rate (± Standard Error): 
Effect of Treatment Drugs on Response to Epinephrine, 2µg. 
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Significant difference between conditions (p <.05) was 
at +20 seconds. 
Figure 5: Mean Percent Change in Heart Rate (± Standard Error): 
Effect of Condition on Response to Epinephrine, 6µg. 
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For determination of significantly different groups (p <,05), 
use the least significant difference values: 
@ 20 seconds 21.08 
@ 30 seconds 20.7 
@ 40 seconds 20.6 
@ 50 seconds 21.2 





4 mg/kg bolus followed by 1 mg/min infusion 
1 mg/kg I.V. followed by saline infusion 
2 ml normal saline followed by saline infusion 
Figure 6: Mean Percent Change PR Segment Duration (±Standard Error): 
Effect of Treatment Drug Injection. 
MEAN PERCENT CHANGE IN PR SEGMENT DURATION (±STANDARD 
ERROR): EFFECT OF TREATMENT DRUG ON RESPONSE TO 
EPINEPHRINE, 2µg 
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For determination of significantly different groups (p <,05), 
use the least significant difference values: 
@ 10 seconds. 12.9 





4 mg/kg bolus followed by 1 mg/min infusion 
1 mg/kg I.V. followed by saline infusion 
2 ml normal saline followed by saline infusion 
Figure 7: Mean Percent Change in PR Segment Duration (±Standard Error): 
Effect of Treatment Drug on Response to Epinephrine, 2µg. 
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For determination of significantly different groups (p <.05), 
use the least significant difference values: 
@ +10 seconds 13.1 
@ +20 seconds 12.4 
@ +30 seconds 13.2 





4 mg/kg bolus followed by 1 mg/min infusion 
1 mg/kg I.V. followed by saline infusion 
2 mg normal saline followed by saline infusion 
Figure 8: Mean Percent Change in QRS Interval (±.Standard Error): 
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For determination of significantly different groups (p <.05), 
use the least significant difference values: 
@ 20 seconds 12.9 





4 mg/kg bolus followed by 1 mg/min infusion 
1 mg/kg I.V. followed by saline infusion 
2 ml normal saline followed by saline infusion 
Figure 9: Mean Percent Change in QRS Interval (± Standard Error): 
Effect of Treatment Drug on Response to Epinephrine, 2µg. 
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Significant difference (p <,05), between conditions occurred 
at +10, +30, +40, +50 seconds. 
Figure 10: Mean Percent Change in PR Segment Duration (± Standard Error): 
Effect of Condition on Response to Epinephrine, 6µg. 
MEAN PERCENT CHANGE IN QRS INTERVAL DURATION 
(zSTANDARD ERROR): EFFECT OF CONDITION ON RESPONSE TO 
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Significant difference (p <,05) between conditions occurred 
at +50 seconds. 
figure 11: Mean Percent Change in QRS Interval (± Standard Error): 
Effect of Condition on Response to Epinephrine, 6µg. 
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treatment group. (This is the mean duration averaged over 60 seconds.) 
Condition affected the mean duration response to epinephrine with a sig-
nificant prolongation of all intervals in the anesthetized state with in-
creasing epinephrine doses. The awake group response was a decrease in 
interval duration. 
For the change in interval significant differences existed between 
1) the lidocaine and xylazine treatments and 2) between the saline and 
xylazine treatments for doses of epinephrine up to 10µg. The mean 
change in response to epinephrine or drug treatment was a significant 
prolongation of intervals for the xylazine group, with usually a decrease 
in interval duration in response to the other two drugs and epinephrine 
(Figures 6-9). Again conditions affected the mean response overall with 
the anesthetized group having the longer interval duration (Figures 
10-12). 
For the change in interval after 10µg the differences existed be-
tween the 1) lidocaine and saline groups and between 2) the xylazine and 
saline groups with no difference between the lidocaine and xylazine treat-
ments. 
Analyses of the percent change in interval duration resulted in the 
same significant differences as the change in interval duration. Factor 
analyses confirmed the results of the original analysis. 
Amplitudes 
The only significant changes occurred with the R amplitude. When 
the treatment drugs were injected, xylazine administration resulted in 
a significant increase in R amplitude above control of lidocaine treat-
ment values. Injection of epinephrine resulted in a decrease in R ampli-
tude for the xylazine group (either a negative change or a smaller po-
sitive change), the change significantly different from either the li-
docaine or saline group, which had an increase in amplitude. 
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For percent change in amplitude, there was no significant difference 
found from the analysis of variance or factor analysis. 
Correlation 
A correlation was run on the actual (raw) data. Although there 
was a significant correlation between some of the parameters measured, 
the only consistently significant correlation was a negative correla-
tion between heart rate and interval duration (p <.05). 
CHAPTER XII 
DISCUSSION 
In the present study, anesthesia was induced with halothane and 
nitrous oxide in oxygen. In association with a more potent anesthetic 
(i.e., halothane) nitrous oxide provides a means for a rapid induction 
and allows for less of the more potent anesthetic to be used (64, 137, 
138). Although addition of nitrous oxide to halothane will result in an 
increased peripheral resistance and mean arterial pressure (139, 141) 
discontinuation of nitrous oxide will allow return of these parameters 
to control levels (140). The nitrous oxide used for induction of anes-
thesia in the present study, therefore, is assumed to have had no effect 
on the other treatments. 
Halothane Anesthesia and Cardiac Arrhythmias 
There are several factors to consider in the genesis of arrhythmias 
under halothane anesthesia. One factor is the PaC02 and associated with 
this is the mode of ventilation (55, 65, 67). In both man and dogs, spon-
taneous ventilation is usually associated with increased PC02 levels, 
which may lead to cardiac arrhythmias after reaching a threshold value. 
The threshold for halothane anesthesia has been shown to be approximately 
60mmHg. In those animals where blood gases were monitored at the onset 
of arrhythmia, the PC02 values did not exceed 40mmHg. Since this measure-
ment was not available in all dogs, it is possible a high PC02 might have 
been a factor in the development of the arrhythmia. 
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The role of blood pressure cannot be determined since arterial pres-
sure was not recorded. By analysis of the heart rate on that dose of 
epinephrine where an arrhythmia was produced (i.e., final dose) it can 
be seen that heart rate possibly played a role in the genesis of 
those arrhythmias. 
A possible explanation for the arrhythmias in the J.idocaine and 
9 
saline groups may be the critical rate for arrhythmiogenesis was reached. 
Except for the individual cases where cardiac arrest occurred .(these 
are included in the analysis), the arrhythmias were usually preceded 
by an increased heart rate. For the dogs receiving xylazine it is pas-
sible that a change in blood pressure was one of the underlying causes of 
the arrhythmias. The reason heart rate may not play a role is that first, 
under halothane anesthesia, heart rate was' initially significantly slower 
compared to the awake group. Secondly, the response to 1ow doses of 
epinephrine under xylazine and halothane was that of a negative change or 
a smaller positive change in heart rate, as compared to the other treat-
ments. The results in this section of the experiment compare to what 
is known about the response to epinephrine under halothane. It is known 
that the heart is less responsive to epinephrine under halothane, although 
the overall sympathetic response is still maintained (142). This can be 
seen in data comparing the two conditions and the response to epinephrine. 
In analyzing the change of heart rate, it was shown the halothane group 
had a lower mean change in heart rate in response to epinephrine, indepen-
·dent of treatment group. When analyzed by treatment, the xylazine group 
had the lowest mean response of the three treatments. The reason blood 
pressure may therefore be more important deals with the a sympathomimetic 
actions of xylazine, accompanied possibly by an increased sensitivity of 
the baroreceptors (7, 133). The effects of lidocaine on heart rate at 
higher doses of epinephrine are statistically similar to the response of 
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the xylazine group. It has been reported that the depressant effects of li-
docaine of Vmax are rate dependent (105). Stimulation of heart rate, espe-
cially by epinephrine, will increase the effect of lidocaine. The pos-
sible mechanism of this may be related to its property of prolonging the 
effective refractory period relative to action potential duration (113)., 
The effect on the sodium channels (prolonging the time for reactivation) 
may also be part of its mechanism. Since xylazine has local anesthesia 
properties (133), perhaps it is through the action on the sodium channel 
that its effect is mediated. The time delay in reactivation of the sodi-
um channel may be the mechanism involved in xylazine's production of 
second degree atrioventricular block. This is a common arrhythmia in 
horses following xylazine administration (136). This effect, however, 
occurred at low doses of epinephrine. Another possible mechanism 
might be that which is proposed for halothane, which is increasing the 
outward potassium current (73, 74). This may account for halothane's de-
pression of the response to epinephrine at all dosage levels. 
Halothane also depresses conduction velocity, which is manifested 
by increased interval duration of the surface electrocardiogram (72). 
In the present study the P wave, PR segment and QRS duration were pro-
longed in the anesthetized group as compared to the awake group. The 
P wave and PR segment represent a decreased atrioventricular conduction. 
Combined with xylazine, the effect of halothane on conduction velocity is 
enhanced. Lidocaine is known to decrease conduction velocity, although 
the decrease is not necessarily seen on the surface ECG (2). In combina-
tion with halothane, the conduction velocity may be depressed further 
and may possibly be demonstrated by the electrocardiogram (48, 72). 
Considering the experimental evidence the production of arrhythmias 
by halothane is most likely due to reentry of impulses (75). Reentry 
requires a slowed conduction and/or unequal distribution of effect on 
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the refractory period, and these are changes known to occur in the myocar-
dium upon exposure to halothane and/or epinephrine (73, 74, 84). Lido-
caine's effectiveness as an antiarrhythmic might be its ability to 
equalize disparity between action potential duration and effective refrac-
tory period in these areas (47, 113, 143). Changes in response to epine-
phrine, seen in the ECG, are decreases in interval duration, except for 
the QT interval, which may be prolonged. Disparity in recovery due either 
to vagal or sympathetic stimulation, may be evidenced by changes in the 
QT interval and T wave form. (The T wave form, however, in the dog is 
extremely variable.) If this is any indication of disparity of recovery, 
the T interval did change in length depending on the dose of epinephrine. 
It should be stressed again that changes in QT interval to epinephrine are 
somewhat variable. In the lidocaine treatment group, QT interval duration 
usually decreases, while in the xylazine group it increases. This last 
observation has been correlated by some authors as evidence of an in-
creased susceptibility to fatal ventricular arrhythmias (51). Another 
point of observation is the interrelation between various intervals. Using 
data from the correlation, it should be noted that at particular doses of 
epinephrine, one particular interval may be positively correlated to ano-
ther interval and negatively correlated to a third. This may relate to 
alterations in refractoriness, which would allow reentry arrhythmias to 
occur ( 92) . 
The amplitude of the R wave may be useful in diagnosing disparity 
between areas in the ventricular conduction system (92). It has been 
shown that amplitude is increased by vagal and decreased by sympa-
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thetic stimulation. This is related to a lower and higher, respectively, 
synchronization of individual ventricular fibers, due to a changed conduc-
tion. It would seem in this instance, the xylazine group and epinephrine 
resulted in a decreased R wave amplitude. This is in contrast.to the 
other two treatments and the results of the anesthetized group (as 
compared to the awake condition). 
CHAPTER XIII 
SUMMARY AND CONCLUSIONS 
Electrocardiographic changes were monitored in response to graded 
doses of epinephrine in awake and halothane anesthetized dogs. The ef-
fects of treatment with lidocaine and xylazine on the response to epi-
nephrine was characterized. 
Halothane anesthesia generally resulted in a lowered heart rate and 
longer PR, QRS, and QT interval durations, when compared to the awake 
group. Injection of all doses of epinephrine (2µg to 18µg in incre-
ments of 2µg) prolonged interval duration and increased heart rate. The 
change in heart rate in response to the epinephrine was significantly 
lower (p <,05) in halothane anesthetized animals than in unanesthetized 
animals. 
In combination with halothane, both lidocaine and xylazine prolonged 
interval durations in the electrocardiogram. Xylazine resulted in a change 
in heart rate and R wave amplitude in response to epinephrine, tending 
to block the epinephrine effect to a greater degree than lidocaine. Li-
docaine had a similar blocking effect at doses of epinephrine greater than 
10µg. 
The characteristics of halothane or epinephrine induced cardiac ar-
rhythmias are an increase in heart rate and prolonged QT interval. Halo-
thane in combination with xylazine resulted in a diminished change in 
heart rate demonstrating its antiarrhythmic effect. However, xylazine 
prolonr,ed the OT interval duration, an event associated with the produc-
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tion of arrhythmias. In contrast, lidocaine resulted in a decrease in 
QT interval duration in response to epinephrine. 
The mechanism of action of xylazine may be similar to that of li-
docaine on the fast inward sodium current, although the time delay in 
reactivation may be greater than for the lidocaine group. 
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APPENDIXES 
TABLE I 
ANALYSIS OF VARIANCE: EFFECT or TREATMENT DRUGS (LIDOChINE, XYLAZINE, SALINE) ON MEAN VALUES 
FOR HEA .. ~T RATE, CHANGE HEART RATE AND PERCENT CHANGE IN HEART RATE 
Lidocaine Xylazine Saline Least 
Standard Standard Standard Significant 
Parameter Injection N mean error N mean error N mean error Difference 
Heart Rate Preinjection 64 90.2 3.30 68 100.58 2.86 66 102.3 3.69 9.96 
Drug Treatment 84 93.3 2.96 84 71.2 2.8 84 101.5 2.8 8.21 
Change in Treatment Drug 
Heart Rate 
+10 seconds 12 3.5 2.38 12 -18.5 8.33 12 1.0 0.67 14.6 
+20 seconds 12 1.5 2.46 12 -26 7.54 12 2.5 1.37 13.6 
+30 seconds 12 4. 5 3.22 12 -37 8. 5.5 12 -1.0 2.19 16.4 
+40 seconds 12 3.5 3.42 12 -37 .5 8.35 12 0.5 1.37 15.9 
+50 seconds 12 3.5 2.80 12 -40 8.90 12 -1.6 1.82 16.8 
+60 seconds 12 4.0 2.50 12 -41.5 8.17 12 -1.0 1.62 15.4 
2µg epinephrine 
+10 seconds 12 15 5.50 12 - 4.6 3.24 12 22 7.58 16.7 
8µg epinephrine 
+10 seconds 10 10.8 7.93 8 - 0.75 3.29 9 32 9.11 22.8 
+40 seconds 9 11.4 7.14 8 0 5.66 6 -22 7.04 20.2 
+50 seconds 8 11.2 7.89 8 - 2.2 5.31 6 -22 8.29 20.7 
+60 seconds 8 20.2 11.99 8 .82 5.40 6 ..-25 9.47 27.5 
10µg epinephrine 
+50 seconds 7 4,2 7.60 8 - 5.2 5.37 5 -30 12.5 20.1 
+60 seconds 7 13.7 11.54 8 ~ 3.0 4,81 4 .,..21 9.0 23.1 
c..o 
0 
TABLE I (Continued) 
Lidocaine Xylazine Saline Least 
Standard Standard Standard Significant 
Parameter Injection N mean error N mean error N mean error Difference 
Change in 
Heart Rate Treatment Drug 
(Continued) 
12µg epinephrine 
+10 seconds 7 24.8 10.42 8 1.5 2.71 4 31.5 16.13 27.5 
+30 seconds 6 - 6.0 8.19 8 3.7 6.89 3 -38 2.00 20.9 
+40 seconds 6 -15.0 6.88 8 9.0 3.00 3 -46 8.00 14.9 
14µ epinephrine 
+30 seconds 6 - 6.0 11.89 7 6.8 4.22 3 -42 6.00 19.0 
+40 seconds 6 -14.0 11.02 7 - 12 .8 4.42 3 -46 8.71 24.4 
Percent 
Change in Treatment Drug 
Heart Rate 
+10 seconds 12 4.66 3.14 12 - 17 7.32 12 1.07 0.72 13.3 
+20 seconds 12 1.95 2.77 12 - 24.6 6.45 12 2.8 1.51 11.9 
+30 seconds 12 4.72 3.14 12 - 34.7 7.55 12 .09 1.38 14.4 
+40 seconds 12 3.96 3.36 12 - 34 7.32 12 .8 1.01 14.1 
+50 seconds 12 3.33 2.96 12 - 37 8.00 12 .82 1.32 15.3 
+60 seconds 12 5.68 3.19 12 - 38.6 7.06 12 .46 1.48 13.9 
2µg epinephrine 
+10 seconds 12 20.8 9.32 12 6.8 4.81 12 21. 5 7.67 22.0 
8µg epinephrine 
+40 seconds 9 14.78 9.19 8 7.96 10. 71 6 - 21.7 7.25 27.1 
+50 seconds 8 12.6 8.71 8 - 11.4 7.93 6 - 22.5 8.55 25.3 
+60 seconds 8 20.0 11.21 8 6.8 8.05 6 - 26.1 10.55 29.5 
lD 
I-" 
TABLE I (Continued) 
Lidocaine Xylazine Saline Least 
Standard Standard Standard Significant 
Parameter Injection N mean error N mean error N mean error Difference 
Percent 
Change in 
Heart Rate Treatment Drug 
(Continued) 10µg epinephrine 
+50 seconds 7 6.9 8.84 8 -10.00 8.50 5 -27.7 11.52 24.8 
+60 seconds 7 18.0 13 .4 8 - 6.6 8.25 4 -20.7 9.27 30.4 
12µ epinephrine 
+40 seconds 6 -14.4 7.26 8 -13 .4 4.55 3 -46.5 6.83 17.1 
16µg epinephrine 
+20 seconds 4 12.4 11.42 7 - 3.6 5.92 3 -33.7 6.87 20.2 
18µg epinephrine 
+20 seconds 3 10.7 15.97 7 - 1.5 12.49 3 -41.5 4.81 28.3 
N = number of observations making up average values 
L.S.D. = least significant divisor - used to determine which groups are significantly 
different at the .05 level 
Values above are mean values for the time interval and dose indicated. All values 
significant at the .05 level 
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TABLE II 
ANALYSIS OF VARIANCE: MEAN VALUES FOR EFFECT CONDITION (ANESTHETIZED, AWAKE) 
ON HEART RATE, CHANGE IN HEART RATE AND PERCENT CHANGE IN HEART RATE 
Anesthetized Awa.ke 
Standard Standard 
Parameter Injection N mean error N mean error 
Heart Rate Preinjection 94 93.8 1. 56 104 101.8 3.35 




Change in 2µg epinephrine 
Heart Rate 
+50 seconds 16 -2.2 2.76 18 12.0 6.35 
+60 seconds 16 -2.0 1. 85 18 10.6 4.6 
4µg epinephrine 
+60 seconds 15 -3.1 3.5 14 9.2 5.3 
8µg epinephrine 
+20 seconds 14 -4.1 4.9 12 11.4 4.7 
+50 seconds 12 -14.2 5.3 10 1. 2 7.3 
+60 seconds 12 -12.2 5.5 10 3.6 11.4 
1oµg epinephrine 
+20 seconds 12 -4.1 5.5 8 26.5 9.0 
+30 seconds 12 -12.2 5.6 8 11. 7 6.0 
+t~O seconds 12 -16.5 4.7 8 0.2 5.0 
+60 seconds 12 -11. 5 4.4 7 14.7 10.7 
12µg epinephrine 
+20 seconds 12 -13.8 5.9 7 13.5 9.4 
+30 seconds 11 -19. 4 6.2 6 10.0 7.0 
+40 seconds 11 -27.3 5.8 6 -5.0 1. 8 
14µg epinephrine 
+20 seconds 10 -16. 8 7.6 6 16.0 8.8 
+30 seconds 10 -27.3 5.9 6 8.0 5.2 
+40 seconds 10 -29.8 6.8 6 -5.0 6.4 
16µg epinephrine 
+20 seconds 9 -14.6 5.6 5 17.5 9.0 
94 
TABLE II (Continued) 
Anesthetized Awake 
Standard Standard 
Parameter Injection N mean error N mean error 
Percent 2µg epinephrine 
Change in 
+60 seconds 16 -2.1 2.1 18 12.9 5.6 Heart Rate 
4µg epinephrine 
+60 ceconds j 5 -2.9 4.2 14 12.2 6.1 
6µg epinephrine 
+20 seconds 15 -2.3 3.2 14 14.4 7.7 
8µg epinephrine 
+20 seconds 14 -3.3 6.1 12 16.7 5.3 
+50 seconds 12 -16.3 5.9 10 7.02 8.7 
+60 seconds 12 -14.1 6.2 10 11. 9 11.8 
10µg epinephrine 
+20 seconds 12 -4.2 5.8 8 33.0 11. 3 
+30 seconds 12 -11. 5 6.4 8 16.4 9.6 
+40 seconds 12 -16.4 4.5 8 -.27 6.3 
+60 seconds 12 -12.1 4.9 7 19.4 14.6 
12µg epinephrine 
+20 seconds 12 -14.5 6.3 7 14.5 10.5 
+30 seconds 11 -18.2 6.8 6 17.2 14.2 
+40 seconds 11 -27.2 5.8 6 -5.6 2.0 
14µg epinephrine 
+20 seconds 10 -17.2 8.9 6 17.0 9.4 
+30 seconds 10 -28.5 5.g 6 9.0 6.5 
1fµg epinephrine 
+20 seconds 9 -16.8 6.1 5 14.8 7.3 
+30 seconds 9 -27.9 6.0 5 7.3 14.2 
N = number of observations 
Times shown are post injection of epinephrine 
or treatment injections (Lidocaine, Xylazine, 
Saline) 
TABLE III 
ANALYSIS OF VARIANCE: EFFECT OF TREATMENT DRUGS (LIDOCAINE, XYLAZINE, SALINE) 
ON MEAN INTERVAL DURA'1'IONS 
Lidocaine Xylazine Saline Least 
Standard Standard Standard Significant 
Parameter Injection N mean error N mean error N mean error Difference 
Pwave Preinj ect ion 64 .0455 • 0015 69 .0467 .0014 66 .0412 .0014 .0044 
duration 
Treatment Drug 84 .0465 • 0013 84 . 0480 . 0012 84 .0414 • 0011 • 0037 (seconds) 
4µg epinephrine 84 .0444 .0012 68 .0531 .0016 68 .0430 .0011 .0039 
6µg epinephrine 80 .0467 .0013 56 .0536 . 0013 63 .0402 .0011 .0038 
14µg epinephrine 39 .0456 .0020 49 .0554 .0012 21 .0530 .0025 .0047 
16µg epinephrine 28 .0423 .0020 49 .0542 .0015 21 .0532 .0023 .0047 
PR segment Treatment Drug 84 .0465 .0013 84 .0484 .0021 84 .0402 .0012 . 0045 
duration 
2µg epinephrine 84 .042/ • 0014 81 .0545 .0024 80 .0379 . 0013 . 0049 
(seconds) 
4µg epinephrine 84 • 0428 . 0013 68 .0571 .0028 68 .0433 .0017 ,0056 
6µg epinephrine 80 .0474 .0017 56 .0603 .0032 63 .0414 .0017 .0062 
8µg epinephrine 65 .0440 .0017 56 .0561 .0030 50 .0481 .0021 .0067 
12µg epinephrine 45 .0506 .0022 55 ,0643 .0033 21~ .0581 .0033 .0090 
16µg epinephrine 28 ,0454 .0029 49 . 0740 .0034 21 .0615 .0038 .0082 
QRS Inter- Treatment Drug 84 .0437 . 0012 84 .0458 .0009 84 .0382 .0009 .0028 
val dura-
4µg epinephrine 84 • 0418 • 0011 68 ,0485 . 0010 68 .0349 .0007 .0029 tion 
(seconds) 6µg epinephrine 80 .0439 . 0013 56 .0480 .0012 63 .0361 .0009 .0036 
Bµg epinephrine 65 . 0414 .0013 56 .0500 .0009 50 . 0404 • 0013 .0035 
10µg epinephrine 49 .0403 .0016 56 .0495 . 0010 34 .0470 .0021 .0045 
12µg epinephrine 45 .0411 . 0018 55 .0507 • 0011 24 .0447 . 0018 . 001~2 tD 
U1 
TABLE III (Continued) 
Lidocaine Xylazine 
Standard Standard 
Parameter Injection N mean error N mean error N 
QT inter-
val dura- 14µg epinephrine 39 .0418 .0018 49 .0507 .0009 21 ti on 
(Continued) 16µg epinephrine 28 . 0375 .0007 49 .0517 .0010 21 
(seconds) 
QT Interval 
duration 2µg epinephrine 84 .2146 .0029 81 .2469 .0028 80 
(seconds) 
16µg epinephrine 28 .2175 .0058 49 .2482 .0032 21 
N = number of observations 
To Determine Difference Between Groups, Use Least Significant Divisor 




















ANALYSIS OF VARIANCE: EFFECT OF CONDITION (ANESTHETIZED OR AWAKE) 
ON MEAN INTERVAL DURATION IN RESPONSE TO TRE~TMENT DRUGS 
(LIDOCAINE, XYLAZINE, SALINE) AND EPINEPHRINB 
Anesthetized Awake 
Standard Standard 
Parameter Injection N mean error N mean error 
Pwave 
Preinjection 95 duration .0463 .0013 104 .0428 .0011 
(seconds) Treatment Drug 126 • 0476 . 0011 126 .0430 .0009 
L~µg epineph!'ine 107 .0486 . 0011 113 .0448 .0011 
6µp.; epinephrine 104 .0498 • 0011 95 .0430 . 0011 
10µg epinephrine 84 .0527 . 0011 55 .0471 .0018 
14µg epinephrine 69 .0558 .0012 40 .0449 ,0016 
16µg epinephrine 63 .0554 .0012 35 .0419 • 0018 
PR seg- Treatment Drug 126 .0511 .0014 126 .0390 .0010 ment 
2µg epinephrine 1-19 duration .0508 .0018 126 . 0396 .0011 
(seconds) 4pg epinephrine 107 .0536 .0019 113 .0415 .0013 
6µg epinephrine 104 .0550 .0020 95 .0427 .0015 
12µg epinephrine 79 .0635 .0025 45 .0487 .0021 
16µg epinephrine 63 . 0718 ,0027 35 .0476 .0029 
QRS Treatment Drug 126 .0464 .0009 126 .0387 .0007 
interval 
4]lg epinephrine 107 .0441 .0010 113 .0395 .0008 duration 
(seconds) 6 fl.E'. epinephrine 104 . 01+55 .oo:u 95 .0394 .0009 
8 Jlf, epfocphrine CJ 3 .0467 .0011 78 .0406 .0009 
10µg epinephrine 84 . 0487 . 0012 55 .0409 . 0013 
12µg epinephrine 79 .0490 .0012 49 .0409 .0012 
14µg epinephrine 69 .0487 .0012 40 .0421 . 0011 
16µg epinephrine 63 .0477 .0012 35 .0437 .0014 
QT Inter- 2i.ig epinephrine 119 .2274 .0036 126 .2154 .0034 val 
16µg epinephri.ne 63 .2453 .0029 duration 35 .2268 .0052 
(seconds) 
TABLE v 
ANALYSIS OF VA..~IANCE: EFFECT OF TREATMENT DRUGS (LIDOCAINE, XYLAZINE AND SALINE) 
ON MEAN CHANGE IN INTERVAL DURATION 
Lidocaine Xylazine Saline Least 
Standard Standard Stanrard Significant 
Parameter Injection N mean error N mean error N mean error Difference 
Change in 2µg epinephrine 
(.05) 
Pwave 




+40 seconds 12 -.0052 .0045 12 .0081 .0035 12 -.0030 .0028 .0107 
14µg epinephrine 
+50 seconds 5 -.0036 .0042 7 -. 0037 .0021 3 .0123 .0023 .0074 
18µg epinephrine 
+40 seconds 3 .0070 .0075 7 .0010 .0005 2 .0195 .0095 .0135 
PR segment Treatment Drug 
duration 
+10 seconds 12 .0034 .0016 12 .0082 .0032 12 -.0001 .0003 .0061 
+20 seconds 12 .0035 .0017 12 .0131 .0042 12 0 .0005 .0079 
+30 seconds 12 .0034 .0019 12 .0128 .0040 12 -.0019 .0012 .0080 
+40 seconds 12 .0017 .0019 12 .0015 .0041 12 -.0009 .0010 .0080 
+50 seconds 12 .0030 .0018 12 .0119 .0044 12 -.0013 .0010 .0083 
+60 seconds 12 .0049 .0024 12 .0145 .0045 12 0 .0009 .0089 
2µg epinephrine 
+10 seconds 12 -.0056 .0021 12 .0024 .0021 12 -.0050 .0019 .0060 
+20 seconds 12 -.0062 .0029 12 .0034 .0027 12 -.0038 .0024 .0075 
+60 seconds 12 -.0049 .0037 11 .0090 .0037 11 -.0018 .0014 .0097 
tO 
ClJ 
TABLE V (Continued) 
Lidocaine Xylazine Saline 
Standard Standard Standard Significant 
Parameter Injection N mean error N mean error N mean error Difference 
PR segment (.05) 
duration 4µg epinephrine 
(Continued) 
+10 seconds 12 -.0055 .0032 11 .0059' .0025 11 .0041 .0034 .0088 
+20 seconds 12 -.0064 .0036 11 .0109 .0043 10 .0040 .0040 .0118 
6µg epinephrine 
+10 seconds 12 -.0040 .0030 8 .0127 .0048 9 -.0062 .0024 .0092 
+20 seconds 12 -.0052 .0034 8 .0082 .0047 9 .0006 .0022 .0103 
QRS Interval Treatment Drug 
duration 
(seconds) +10 seconds 12 .0008 .0006 12 .0028 .0029 12 -.0043 .0018 .0057 
+20 seconds 12 .0003 .0006 12 .0034 .0023 12 -.0039 .0018 .0052 
+30 seconds 12 .0018 .0013 12 .0063 .0017 12 -.0020 .0021 .0053 
2µg epinephrine 
+20 seconds 12 -.0015 .0022 12 .0050 .0013 12 -.0044 .0026 .0063 
+30 seconds 12 .0002 .0027 12 .0039 .0015 11 -.0032 .0010 .0054 
+40 seconds 12 .0029 .0031 11 .0040 .0023 11 -.0039 .0011 .0069 
6µg epinephrine 
+10 seconds 12 -.0041 .0018 8 .0053 .0027 9 .0024 .0026 .0069 
+50 seconds 11 -.0006 .0016 8 .0086 .0045 9 .0017 .0022 .0075 
8µg epinephrine 
+60 seconds 8 -.0025 .0008 8 .0020 .0015 6 .0093 .0041 .0073 
<D 
<D 
TABLE V (Continued) 
Lidocaine Xylazine Saline 
Standard Standard Standard Significant 
Parameter Injection N mean error N mean error N mean error Difference 
QRS Interval Treatment 
duration 10µg epinephrine (seconds) 
+20 seconds 7 -.0004 . 0011 8 -.0031 .0027 5 .0088 .0038 .0081 
+50 seconds 7 • 0014 .0012 8 .0002 .0033 5 .0136 • 0048 .0099 
+60 seconds 7 .0002 • 0011 8 -.0001 .0034 4 .0152 .0063 • 0115 
QT Interval Treatment 
duration 
+40 seconds 12 .0021 .0075 12 • 0215 .0065 12 -.0013 .0014 .0176 
+50 seconds 12 .0042 .0056 12 .0235 .0068 12 -.0044 .0029 .0166 
+60 seconds 12 .0046 .0053 12 .0250 .0059 12 -.0029 .0031 . 0155 
2µg epinephrine 
+10 seconds 12 -.0144 .0056 12 .0123 .0064 12 -'-. 0032 .0052 .0173 
+20 seconds 12 -.0152 .0060 12 .0141 .0064 12 -.0021 .0064 .0180 
+30 seconds 12 -.0122 .0063 12 .0168 .0065 11 -.0064 .0052 .0173 
+40 seconds 12 - . 0106 .0065 11 .0148 .0098 11 -.0025 .0056 . 0203 
+50 seconds 12 -.0112 .0064 11 .0106 .0076 11 -.0026 • 0052 .0176 
8µg epinephrine 
+20 seconds 10 -.009 .0047 8 .0025 .0072 8 . 0103 .0038 .0148 
QT Interval 10µg epinephrine 
duration 




TABLE V (Continued) 
Lidocaine Xylazine Saline 
Standard Standard Standard Significant 
Parameter Injection N mean error N mean error N mean error Difference 
QT Interval 
duration 10µg epinephrine 
+40 seconds 7 -.0057 .0058 8 -.0010 .0047 5 .0444 .0114 .0225 
+50 seconds 7 -.0075 .0052 8 -.0046 .0062 5 .0354 .0119 .0247 
+50 seconds 7 -.0080 .0052 8 -.0040 .0062 4 .0322 .0135 .0243 
14µg epinephrine 
+10 seconds 6 -.0065 .0060 7 .0104 .0051 3 -.0183 .0099 .0204 
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TABLE VI 
ANALYSIS O~ VARIANCE:EFFECTS OF CONDITION (AWAKE, ANESTHETIZED) 
ON RESPONSE TO EPINEPHRINE OR TREATMENT INJECTION 
(LIDOCAINE, XYLAZINE, SALINE) 
:MEAN CHANGE INTERVAL DURATION: p <.05 
Anesthetized Standard Awake Standard 
Parameter Injection N mean error N mean error 
P wave 2µg epinephrine 
duration +10 seconds 18 .0037 .0022 18 -.003 .0022 
4µg epinephrine 
+40 seconds 15 .0034 .0024 15 -.003 .0018 
6µg epinephrine 
+10 seconds 15 .0024 .0019 14 -.004 • 0018 
+30 seconds 15 .0024 .0022 14 -.0042 • 0018 
+40 seconds 15 .0042 .0019 13 -.0023 .0014 
+50 seconds 15 .0050 .0023 13 -.0023 .0017 
+60 seconds 14 .0043 .0024 13 -.0028 • 0018 
10µg epinephrine 
+20 seconds 12 .0047 .0020 8 -.0032 .0012 
12µg epinephrine 
+20 seconds 12 .0036 .0029 7 -.0051 .0019 
14µg epinephrine 
+30 seconds 10 .0045 .0027 6 -.0076 .0031 
+40 seconds 10 .0065 .0029 6 - • 0071 .0027 
+50 seconds 10 .0035 .0025 5 -.0084 .0028 
+60 seconds 9 .0052 .0020 5 -.0078 .0047 
PR Segment 6µg epinephrine 
duration 
+10 seconds 15 .0041 .0036 14 -.0045 .0028 
+30 seconds 15 .0086 .0043 14 -.0038 .0030 
+40 seconds 15 • 0116 .0044 13 -.0047 .0024 
+50 seconds 15 .0119 .0038 13 -.0010 .0025 
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Table VI (Continued) 
Anesthetized Standard Awake Standard 
Parameter Injection N mean error N mean error 
PR segment 14µg epinephrine 
duration +30 seconds 10 .0143 .0029 6 -.0008 • 0071 
+40 seconds 10 .0162 .0036 6 .0018 .0066 
+50 seconds 10 .0018 .0033 5 .0010 .0081 
+60 seconds 9 . 0177 .0024 5 -.0088 .0046 
PR Segment 16µg epinephrine 
duration +40 seconds 9 .0207 .0043 5 .0010 .0039 
+50 seconds 9 .0248 .0045 5 .0002 .0023 
+60 seconds 9 .0232 .0032 5 .0094 .0063 
QRS Interval 6µg epinephrine 
duration 
+50 seconds 15 .0058 .0028 13 - . 0007 . 0010 
+60 seconds 14 .0046 .0018 13 0 . 0011 
14µg epinephrine 
+20 seconds 10 .0018 .0014 6 -.0025 .0012 
QT Interval Preinjection 
duration 
+30 seconds 18 -.002 .0046 18 .0016 .0060 
6µg epinephrine 
+40 seconds 15 .0140 .0064 13 -.013 .0085 
+50 seconds 15 .0099 .0065 13 -.014 .0066 
8µg epinephrine 
+40 seconds 13 .0126 .0076 10 -.015 .0087 
+50 seconds 12 .0205 .0081 10 -.017 .0086 
+60 seconds 12 .0225 .0076 10 -.013 .0078 
10µg epinephrine 
+30 seconds 12 .0124 .0078 8 -.005 .0059 
N = Number of Observations 
Mean = Mean Value Averaged by Dog & Drug Treatment 
All Values Significant at .05 level 
TABLE VII 
ANALYSIS OF VARIANCE:EFFECT OF TREATMENT DRUG~ (LIDOCAINE, XYLAZINE, SALINE) 
ON MEAN PERCENT INTERVAL DURATION (p <.05) 
Lidocainest , d Xylazine Standard Saline Standard Least anaar 
}3i~¥if ican t Parameter Injection N mean error N mean error N mean error i erence 
P wave 2µg epinephrine 
duration 
+20 seconds 12 -7.81 9.31 12 21.3 9. 71 12 -5.8 6.19 (. 05) 
12µg epinephrine 
+40 seconds 6 30.6 7.2 8 -3.7 4.7 3 21.4 24.4 
14µg epinephrine 
+50 seconds 5 -7.6 9.0 7 -6.8 3.85 3 29.1 10.4 
PR segment Treatment Drug 
duration 
+20 seconds 12 8.90 4.8 12 3.37 11.4 12 .208 1.4 21.08 
+30 seconds 12 9.02 4.9 12 30.98 10.8 12 -3.5 2.4 20.7 
+40 seconds 12 4.69 s.o 12 29.8 11.3 12 -1.6 2.4 20.65 
+so seconds 12 8.87 5.0 12 31. 7 11.9 12 -2.7 2.3 21.27 
+60 seconds 12 14.63 7.2 12 39.7 12.8 12 -.13 2.3 24.94 
2µg epinephrine 
+10 seconds 12 -10.2 3.8 12 5.17 5.2 12 -12.12 4.3 12.96 
' 
+60 seconds 12 -7.47 5.9 11 18.13 8.8 11 -4.38 3.5 19.55 
6µg epinephrine 
+10 seconds 12 -7.65 5.4 8 31.81 13.1 9 -13.2 4.8 21.26 
QRS Interval Treatment Drug 
duration 
+10 seconds 12 1.94 1.43 12 9.94 7.1 12 -9.15 3.7 13.11 




TABLE VII (Continued) 
Lidocaines d d Xylazine Standard SalineStandard 
Least 
tan ar 
~iffificant Parameter Injection N mean error N mean error N mean error 1 erence 
(.05) 
+ao seconds 12 3.53 2.85 12 16.90 4.9 12 -2.87 5.2 13.25 
+50 seconds 12 -.048 3.07 12 16.3 7.1 12 -5.02 4.8 15.08 
2µg epinephrine 
+20 seconds 12 -1. 84 5.06 12 10.83 3.30 12 -9.5 4.6 12.97 
+30 seconds 12 3.34 6.5 12 8.13 3.10 11 -8.27 2.5 12.65 
6µg epinephrine 
+10 seconds 12 -8.97 3.7 8 14.02 7.2 9 7.60 8.2 18.25 
8µg epinephrine 
+60 seconds 8 -.351 1.96 8 3.80 3.05 6 26.23 12.50 20.45 
QRS Interval10µg epinephrine 
duration +20 seconds 7 -1.02 3.23 8 -5.41 4.8 5 21.91 9.5 17.32 
+50 seconds 7 4.23 3.41 8 2.08 6.4 5 36.25 14,0 24.31 
+60 seconds 7 -.46 3.14 8 1.05 6.5 4 40.58 18.9 27.48 
QT Interval Treatment Drug 
duration 
+60 seconds 12 2.02 2.97 12 11.69 2.74 12 -1.05 1.40 7.32 
2µg epinephrine 
+30 seconds 12 -5.06 2.6 12 7.47 3.0 11 -2.94 2.48 7.74 
"+40 seconds 12 -4.22 2.7 11 7.37 4.6 11 -1.18 2.68 9.51 
+50 seconds 12 -4.59 2.7 11 5.19 3.4 11 1.40 2.58 7.99 
8µg epinephrine 
+20 seconds 10 -4.14 2.18 8 1.81 3.07 8 8.45 3.66 8.44 
I-' 
+30 seconds 10 -3.58 2.73 8 1.16 4.02 6 12.12 3.33 10.26 
0 
c.n 
TABLE VII (Continued) 
Lidocaines d d Xylazine Standard 
Saline Standard 
Least tan ar 
}ji¥¥ificant Parameter Injection N mean error N mean error N mean error i erence 
(. 05) 
+40 seconds 9 -6.31 3.53 8 1. 86 5.33 6 14.19 5.71 13.29 
+50 seconds 8 -5.82 4. 51 8 3.05 5.83 6 14.35 5.77 14.59 
+60 seconds 8 -4.79 4. 63 8 5.80 4.93 6 13.66 6.12 13.85 
lOug epinephrine 
+40 seconds 7 -2.6 2.70 8 -.18 2.1 5 29.2 5.5 10.3 
+50 seconds 7 -3.3 2.46 8 -1. 5 2.6 5 42.2 24.7 33.6 
+60 seconds 7 -3.5 2.55 8 -1.2 2.6 4 49.6 34.9 40.9 
14ug epinephrine 
+10 seconds 6 -3.04 2.94 7 4.34 2.19 3 -7.04 3.73 8.89 
N = Ntmlber of Observations 
Mean = Mean Value Averaged over Dog and Condition 
Least Significant Divisor is used to distinguish difference between groups at .05 
level of significance. 
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TABLE VIII 
ANALYSIS OF VARIANCE:EFFECT OF CONDITION (AWAKE OR ANESTHETIZED) 
ON RESPONSE TO TREATMENT DRUG OR EPINEPHRINE 
:PERCENT CHANGE INTERVAL DURATION: 
Anesthetized Standard Awake Standar(J. 
Parameter Injection N mean error N mean error 
PR Segment 6µg epinephrine 
+10 seconds 15 12.18 8.95 14 -9.9 5.42 
+30 seconds 15 24.31 8.67 14 -7.0 6.85 
+40 seconds 15 27.7 9.70 13 -9.9 5.49 
+50 seconds 15 26.5 8.29 13 .06 6.20 
14µg epinephrine 
+40 seconds 10 33.4 8.02 6 2.86 13.13 
+60 seconds 9 39.4 10.52 5 -17.4 9.01 
16µg epinephrine 
+50 seconds 9 47.4 11.31 5 -.83 4.90 
QRS Interval 6µg epinephrine 
duration +50 seconds 15 17.4 8.15 13 -1.6 2.62 
16µg epinephrine 
+30 seconds 9 5.93 2.41 5 -3.7 1.53 
+40 seconds 9 5.5 2.36 5 -4.0 2.34 
+50 seconds 9 5.2 2.35 5 -4.0 2.34 
QT Interval 6µg epinephrine 
duration +40 seconds 15 6.5 2.93 13 -5.6 3.38 
+50 seconds 15 4.8 2.98 13 -6.0 2.64 
8µg epinephrine 
+40 seconds 13 7.9 3.9 10 -6.0 4.0 
+50 seconds 12 11.6 4.0 10 -7.5 3.6 
+60 seconds 12 12.5 3.8 10 -6.0 3.4 
18µg epinephrine 
+60 seconds 6 8.07 2.40 4 -4.0 4.20 
TABLE IX 
ANALYSIS OF VARIANCE FOR EFFECT OF TREATMENT DRUn (LIDOCAINE, XYLAZINE, SALINE) 
ON R WAVE AMPLITUDE (p <.05) 
Lidocaine 
Standard Xylazine Standard Saline Standard Least 
Bi¥¥if icant Parameter Injection N mean error N mean error N mean error J. erence 
R Wave 8µg epinephrine 65 1. 38 .062 56 1.29 .050 50 1. 55 .084 .19 
Amplitude 
Change in Treatment Drug 
R Wave 
+20 seconds 12 -.089 .042 Amplitude 12 .110 .052 12 -.051 .031 .11 
+30 seconds 12 -.059 .018 12 .141 .056 12 -~057 .037 .11 
+40 seconds 12 -.018 .025 12 .125 .043 12 -.018 .026 . 09 
+50 seconds 12 -.007 .025 12 .125 .04-3 12 -.041 .026 .09 
+60 seconds 12 -. 021 .032 12 .092 .045 12 -.075 .048 .12 
VITA 1 
Howard Jeffrey Mass 
Candidate for the Degree of 
Master of Science 
Thesis: ELECTROCARDIOGRAPHIC CHANGES IN RESPONSE TO EPINEPHRINE IN THE 
AWAKE AND HALOTHANE ANESTHETIZED DOG: EFFECT OF TREATMENT WITH 
LIDOCAINE AND XYLAZINE. 
Major Field: Physiological Sciences 
Biographical: 
Personal Data: Born in Brooklyn, New York, April 18, 1954, the son 
of Gerald and Lillian Mass. 
Education: Graduate from Lenape High School in May, 1972; received 
the Bachelor of Arts degree from University of Delaware in 
May, 1976Jwith a major in biology; completed requirements for 
the Master of Science degree at Oklahoma State University, 
July, 1980, with a major in Physiological Sciences. 
Professional Experience: Teaching assistant, Department of Physio-
logical Sciences, Oklahoma State University, September, 1977 
to May, 1980; teaching Introductory Physiology Laboratory and 
Veterinary Physiology Laboratory; laboratory assistant in 
Department of Physiological Sciences, Oklahoma State Univer-
sity, May, 1979 to August, 1979. 
